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THE NOVEL REGULATION OF HISTONE MODIFICATION
IN CANCER DEVELOPMENT
Xian Zhang
Advisory Professor: Hui-Kuan Lin, Ph.D

Dynamic changes in histone acetylation by various physiological cues play
important roles in gene transcription and cancer. However, the cellular
signaling underlying this regulation is not well understood. Here, we show that,
in a glucose dependent manner, E3 ubiquitin ligase NEDD4 ubiquitinates
histone H3 on previously unstudied lysine (K) 23/36/37 residues, which
specifically recruits histone acetyltransferase (HAT) GCN5 for subsequent H3
acetylation. Genome-wide analysis of chromatin immunoprecipitation followed
by sequencing (ChIP-seq) data sets reveals that NEDD4 regulates glucoseinduced H3K9 acetylation at transcription starting site (TSS) and enhancer
regions. Integrative analysis of ChIP-seq and microarray data sets also reveals
a consistent role of H3 ubiquitination in transcription activation and H3 K9
acetylation in response to glucose. Functionally, we showed that NEDD4mediated H3 ubiquitination is critical for tumorigenesis and that IL1A, IL1B
and GCLM are important target genes to elicit the function of glucose-induced
H3 ubiquitination in tumor sphere formation. Together, our study provides a
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new model for glucose-induced transcriptome reprograming and epigenetic
regulation in cancer through inducing NEDD4-dependent H3 ubiquitination.
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Chapter 1 Introduction
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1.1 Chromatin dynamics
1.1.1 Chromatin structures
The term ‘phenotype’ in biology is used to describe an observable characteristics
or traits of an organism. Advances in technology leads to the observation of many
phenotypes beyond our bare eyes, including phenotypes that exists at molecular or atomic
level. Generally, phenotypes of an organism are the reflection of the interaction between
genotypes and environmental factors. Genotypes refers to the complete set of genes in an
organism. Genes are coded and carried by DNA double helix, which is a cellular
macromolecule that is composed of deoxyribonucleotide acids. In eukaryote, the number
and size of genes are so large that the DNA molecule carries it becomes extremely long,
which is many orders of magnitude longer than the diameter of the nucleus (1). To fit
such an long string into the relative small size of the round shaped nucleus, eukaryotic
genomes are packed into dense structures, known as chromatin (2, 3). The basic structure
units of chromatin are the nucleosomes, which are formed by wrapping approximately
every 147 base pairs of DNA double strand around a protein complex. The complex is
composed of of eight core histone proteins, which are two copies of each histone H3, H4,
H2A and H2B (4). The tandem repeat of nucleosome structures are connected by linker
DNA, which is also called beads-on-a-string or 10nm fibre, is the euchromatin region of
chromatin(5). With linker histone H1, multiple nucleosomes on the ‘string’ in some part
of the chromatin are further packaged into 30nm fibers structures to form heterochromatin
region of chromatin(5). During mitosis, 30nm fiber structure further packed into higher
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level of structure is called metaphase chromosome(6). Thus, the changes in structure of
chromatin are closely related to their biological function and will be discussed later.

1.1.2 Histone variants
There are five kinds of histone protein, which are H2A, H2B, H3, H4 and H1 as described
above (4). Generally, DNA binds to core histone complex non-specifically (5). One of
the notable characteristics of histone proteins is the large numbers and distinctive
functions of their variants (7). Histone variants usually differ from their respective
canonical ones from several amino acids or the addition of a large domain (7). Histone
variants can be classified into replicative and replacement types according to their spatial
and temporal involvement in the nucleosome structure (8). Replicative variants are
transcribed in high amounts from tandemly arranged genes (different genes for the same
protein) during S phase to ensure the replication of chromosome (9). Replacement
histones are synthesized throughout the cell cycle and can be integrated into chromosome
in a replication-independent manner (10). Each histone variant has a unique feature in
sequence and thus enables it to interact with specific chromatin factors or DNA structures
involved in various biological processes. For example, the incorporation or eviction of
histone H3.3 by the histone chaperone, HIRA, occurs during cycle and is involved in the
regulation of transcription, while H3.1 and H3.2 are only incorporated during replication
(11, 12). Some of the histone variants are tissue specific or functional specific. CENPA,
a large variant of H3 conveys special functions on the centromere, H3T is only expressed
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in testes or sperm and H2AX is critical for the DNA damage response and DNA repair
process (13-15).

1.1.3 Chromatin remodelers
As I have mentioned previously, environmental factors can also contribute to the
changes of phenotypes. Mutations in gene sequence, that can be induced by mutagens,
may result in the changes of amino acid sequence and the structure of target protein,
leading to the alteration in phenotypes. More frequently, a relative milder environmental
factor may affect the organism at the epigenetic level, including stable changes in DNA
methylation or histone modifications (16). Epigenetic changes often result in the
reprograming of gene expression patterns, which are also closely linked to biological
characteristics (16). In eukaryotes, genes are first transcribed to RNA, the process of
which involves the binding of transcription machinery to the DNA double strand,
indicating that an open status of DNA double strand is required for the transcription
machinery to work (17). Hence, the basal status of eukaryotic genome is transcription
suppressive as DNA is packaged to chromatin. To activate gene transcription, chromatin
regions containing target genes have to be locally opened up for the access of transcription
machinery. In various model organisms, it has been found that the chromatin structure is
dynamic, including the events of opening up of chromatin for active transcription and
closing off of chromatin for transcription repression. These processes are achieved by a
number of chromatin remodeling proteins, which often form larger complexes containing
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functional specialized subunits (18, 19). Based on the functional definition, all chromatin
remodelers share some basic properties, including the capability to bind to nucleosome,
a DNA-dependent ATPase domain for trans-locating DNA from histone contact (DNA
translocase), and the regulatory domains interacting with chromatin-associated factors
and controlling the DNA translocase activity (20). Chromatin remodeler complexes are
able to repositioning, ejecting, unwrapping, exchanging histone from nucleosome
structures (20). Thereby, through regulating the direct accessibility of RNA polymerase
II at specific chromatin sites, chromatin remodeler complexes could promote or inhibit
transcription activity at multiple stages including transcription initiation, elongation and
termination. Moreover, chromatin remodeler complexes also actively participate in other
biological processes which require the access to DNA double strand within chromatin
structure, including DNA replication, DNA repair and DNA recombination (21, 22). In
human, the chromatin remodelers complexes are divided into four conserved families,
namely SWI/SNF ISWI, CHD, INO80 family remodelers (Table 1). Each of them is
composed of different ATPases and non-catalytic homologous subunits, which convey
chromatin locus specificity and functional specialization (17).
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SWI/SNF

Complex
ATPase
Non-catalytic subunits

BAF
hBRM/BRG1
BAF250/hOSA1

ISWI

Complex
ATPase
Non-catalytic subunits

NURF
SNF2L
BPTF
bAp46, 48

CHD

Complex
ATPase
Non-catalytic subunits

CHD1
CHD1

INO80

Complex
ATPase
Non-catalytic subunits

INO80
hIno80

Arp5, 8
hles2, 6

PBAF
BRG1
BAF180
BAF200
BAF155, BAF170
BAF60a, b, c
hSNF5/BAF47/INI1
BAF57
BAF53a, b
b-actin
CHRAC
ACF
SNF2H
hACF1/WCRF180
hCHRAC17
hCHRAC15
NuRD
CHD3, CHD4
MBD3
MTA1, 2, 3
HDAC1, 2
RbAp46, 48
p66a, b
SRCAP
TRRAP/Tip60
SRCAP
p400
RUVBL1, 2/Tip49a, b
BAF53a
Arp6
Actin
GAS41
DMAP1
YL-1
H2AZ, H2B
Brd8/TRC/p120
ZnF-HIT1
TRRAP/Tip60
Tip60
MRG15
MRGX
FLJ11730
MRGBP
EPC1
ING3

Table 1 The classification of chromatin remodelers in human (17).
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1.1.4 Histone chaperones.
Another group of critical factors in chromatin dynamics is the histone chaperones.
They all bind histones and are broadly involved in histone transport, storage, nucleosome
assembly and disassembly (23). Histone chaperones can be classified based on their
binding substrates. Most of the histone chaperones specifically bind to H2A-H2B or H3H4 oligomers, but a few of them recognize free histones, distinguishing the canonical
ones and their variants (Table 2). Unlike the ATP dependent remodelers, histone
chaperones utilize the spontaneous movement of the DNA around the dyad axis of
nucleosome to destabilize the nucleosome, the process of which is slower than chromatin
remodeling (20). Histone chaperones can also facilitate the histone exchange or regulate
transcriptional activity by aiding the histone post translational modification (PTM)
process at the desired locus. For instance, Rtt109-mediated H3K56 acetylation in the
yeast is important for transcription initiation and elongation, but Rtt109 alone is not able
to acetylate H3 within a nucleosome. Histone chaperone Asf1 mediated dissemble of
nucleosome is required for Rtt109 to access H3 for acetylation (24). Similarly, histone
methyltransferase Set2 also requires histone chaperone Spt6 for histone access and
effective methylation (25). Thereby, histone chaperone mediated regulation of histone
PTMs in turn alters the chromatin structures for transcription or other biological processes
by its intrinsic chemical properties or by recruiting specific chromatin remodelers (20).
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Histone Chaperone
HIRA
NAP1
FACT
ANP32E

Histone bound
H3.3
H2A-H2B, H2A.Z-H2B
H2A-H2B
H2A.Z-H2B

Modulated event
H4S47 phosphorylation by PAK2
RSC remodeling
H2BK120 ubiquitination by Rad6, H3K36 methylation by Set2
Unknown

Table 2 Substrate and function of histone chaperones in human (20).
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1.2 Histone modification and its biological function
1.2.1 Histone acetylation
The regulation or specialization of chromatin remodelers or histone chaperones at
targeted chromatin locus or biological processes are largely achieved by histone
modification, which is the covalent PTM on the histone proteins. For example, histone
chaperones are required for histone modification at normally inaccessible sites, in turn,
specific histone modification also facilitates or inhibits the histone exchange by recruiting
or repelling chromatin remodelers or histone chaperones. For example, the binding of
histone chaperone HIRA and its specific histone substrate H3.3 is facilitated by PAK2dependent H4 S47 phosphorylation, which disfavors its interaction with CAF1 (26).
Rtt109 mediated H3 K56 acetylation facilitates histone exchange and transcription
initiation, but Set2-mediated H3K36 methylation restricts histone exchange and
transcription (25, 27). Thus to study the histone PTMs is important in understanding the
regulation of chromatin structure and transcription.
Generally, histone proteins are heavily post-translationally modified by
phosphorylation, acetylation, methylation, ubiquitination and etc., which exert various
functions in regulating chromatin structure through various mechanisms (28, 29). Histone
acetylation is one of the well-known histone modifications that are frequently decorated
at K4, K9, K14, K18, K23, K27, K36 residues on histone H3 and K16 on H4 (30). Histone
acetylation at multiple sites is important, but sometimes is redundant for opening
chromatin and activation of gene transcription (31, 32). Histones acetylation at lysine

10

residues on the one hand neutralizes its positive charge, thereby reducing the affinity
between histone and negatively charged DNA. On the other hand, it recruits specific
chromatin remodeler complexes that recognize acetylated lysine residue on histone
proteins (33). The recognition requires specialized protein domains, including bromo
domain and tandem PHD domain, which are shared features in some chromatin
remodelers (34, 35). Histone acetylation, in essence, is an outcome of transferring an
acetyl group from acetyl-CoA to the lysine residues on histone protein by specific
enzymes known as histone acetyltransferases (HATs) that are often resides in larger
chromatin remodeling complexes. Distinct families of HATs, including GNATs, MYST
HATs and others, have been independently discovered and are responsible for histone
acetylation (36, 37). It is generally believed that a HAT could target multiple lysine
residues on histone and a lysine residue on histone could also be modified by multiple
HATs (37). There might be some extend of redundancy in HAT functions, but emerging
studies have indicated the substrate or lysine residue preference of HATs and the
differential activity of HATs under curtain cellular contexts (38, 39). In the future study,
a related question would be whether there is a preference in the usage of HAT under
curtain physiological cue and, if yes, what would be the underlining mechanism to convey
the specificity.
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1.2.2 Histone methylations.
Unlike acetylation that only occurs on lysine, histone methylation could be
conjugated on arginine, lysine and histidine (40). A single lysine residue could be monomethylated, dimethylated or trimethylated on their ε-amine group. Lysine methylation on
H3K4, H3K9, H3K27, H3K36, H3K79 and H4K20 are relatively well studied in the
chromatin biology field, however, arginine methylation on H3-H4 and many other
methylation events on H2A-H2B have also been identified by recent quantitative mass
spectrometry analysis and their functions remain to be determined (41, 42). Histone
methylation is catalyzed by histone methyltransferases, which are composed of three
families including SET domain containing proteins and DOT1-like proteins for lysine
methylation and protein arginine N-methyl-transferase family for the arginine
methylation (41). Traditionally, it is believed that histone methylations are relative stable
modifications and their turn over rates are much slower than other histone modifications
until the discovery of histone demethylases, which actively and site specifically remove
histone methylation. There are two families of demethylases, including amine oxidases
and jumonji C domain containing iron dependent dioxygenases for lysine demethylation
(43, 44). Arginine demethylases remain to be discovered, although monomethyl arginine
can be converted to citrulline by PADI4 (45). The precise recruitment of
methyltransferases and demethylases to their target histones is an important area of study.
Consensus DNA sequences have been identified as binding sites for several histone
remodeling complexes containing methyltransferase and demethylase. For example,
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polycomb group response elements directly recruit polycomb repressive complex 2
(PRC2), which could catalyze H3 K27 trimethylation, though DNA binding transcription
factors that recognize consensus DNA elements (46, 47). Long non-coding RNAs
(LncRNA) are known to interact with DNA sequences with high sequence specificity,
and are reported to be adaptors in the targeted methylation and demethylation process.
LncRNAs have been shown to interact with PRC2 complex and H3K4 methyltransferase
complex member WD repeat domain 5 (WDR5) (48, 49). With the identification of large
number of lncRNAs in human, it is possible that they may mediate a great many of gene
specific regulations and may be the major mechanism for gene specific interaction
between DNA and chromatin factors. Histone methylations are recognized by proteins
with methyl-binding domains, including PHD finger, WD40 repeat, CW domain, PWWP
domain, ankyrin repeat and royal superfamily, which further includes chromo domain,
double chromo domain, chromobarrel, tudor domain, double or tandem tudor domain and
MBT repeats (42). Since methylation generally adds a positive charge and hydrophobicity
to lysine and arginine, any proteins with hydrophobic properties, aromatic cages and
composite pockets could potentially bind to histone methylations (42). Unlike histone
acetylation, it is more clear that the location and degree of methylation are both critical
for its biological functions. For example, H3 K4 trimethylation is generally a marker for
transcriptional activation, while H3 K27 trimethylation is a repressive marker for
chromatin (50, 51). H3 K79 dimethylation is crucial in cell cycle regulation, but H3 K79
trimethylation is associated with the Wnt signaling pathway (52, 53). Interestingly, the
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transcriptional activation marker H3K4 methylation, when binding to PHD domain
containing co-repressor protein inhibitor of growth family member 2 (ING2), are
associated with the repression of transcription (54). Hence, to study the dynamic changes
of histone methylation is important to understand epigenetic regulations in various
cellular processes.

1.2.4 Quantitative mass spectrometry and novel histone modifications.
Studies of histone modification often involve the generation of site specific
antibodies. However, except for the issue of antibody specificity, antigen occlusion is a
severe issue for such a densely post translationally modified protein, like histone proteins.
Quantitative mass spectrometry (MS) is developed for PTM study and could
simultaneously identify large numbers of PTMs on a large number of proteins in a much
less biased way for biological samples under various conditions (55). Basically, total
proteins were extracted and solubilized. Trypsin protease is commonly used for
generating MS “friendly” peptides, while other proteases might also be used alone or in
combination if the digestion pattern of trypsin is not ideal in some biological samples.
Unlike traditional MS, quantitative PTM MS usually requires an additional enrichment
step, including the usage of chemical, antibody or protein affinity to enrich the specific
modification of interest. The best example would be the development of an antibody that
specifically recognizes di-Glycine linked lysine, which is the left over modification of
ubiquitinated lysine after trypsin digestion (56). Using this antibody, cellular
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ubiquitinated proteins can be enriched before MS identification, which is used to be very
inefficient in identification of protein ubiquitination. Enriched peptides were then sent for
standard shot gun MS and subsequent computational analysis with optimized parameters
for identifications of specific PTMs. Particularly, to generate data with high reliability, it
is important to estimate the sufficient hits to cover the complete model peptides catalogs
in the MS experiments. However, it is very difficult to generate the complete model
catalogs for total cellular PTMs with current computational resources due to the great
number of possible PTMs and PTM combinations on the same protein. Also, modern MS
generated far less than sufficient hits for such a big model set of PTMs (57). Despite the
robustness in study the global PTMs, it is relatively capable of discovering and
quantifying the PTMs on limited protein targets, like histone proteins. Now, quantitative
MS has broadened our view in histone modifications, since many novel and exotic PTMs
were found, such as crotonylation, 2-hydroxysobutyrylation, malonylation, succinylation
and etc. (58) Functional characterization of such modifications would be important follow
up works for PTM MS and may create a new paradigm for chromatin biology.

1.3 Regulation of histone modification
1.3.1 Metabolism dependent regulation of histone modification.
Eukaryotic cells adapt to changes in its environment to survive and proliferate. As
mentioned earlier, the most important adaptation is achieved by a precise reprogramming
of gene expression to fine-tune the cellular functions in face of environmental conditions.
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The dynamics of histone modification are critically responsible for the altered gene
transcription. With regard to stress-induced changes in histone modification, there are
basically two aspects. One is the stress sensing machinery in the cells to transduce
environmental changes to cellular signaling pathways, the other one is the activated
signaling cascades that eventually activate the histone modification enzymes to regulate
gene transcription (59). Alternatively, environmental changes like metabolism related
changes have been shown to regulate histone modification directly, as many metabolic
intermediates are co-factors or substrates for the enzymatic reaction of histone
modifications (60). Glucose deprivation, which causes a rapid decrease in cellular energy,
is proposed to affect histone acetylation through depletion of cellular acetyl-CoA and/or
elevating the NAD+/NADH ratio, which inhibits HATs but activates histone deacetylases
(HDACs), such as Sirtuin (61).
Another important histone modification affected by metabolism is the histone
methylation. All histone methyltransferases use S-adenosyl-methionine (SAM) as a
methyl donor for methylation and also produce S-adenosyl-homocycsteine (SAH), which
is an inhibitor of SAM on a similar reaction order (62). Thus fluctuation of cellular levels
of SAM/SAH may affect histone methylation. SAM is synthesized from methionine and
ATP. SAH is converted to homocysteine, which can be either degraded or re-enter into
the SAM cycle through re-methylation to methionine. These reactions are all essentially
dependent on vitamins, especially folate, vitamin B6 and vitamin B12 (63). Thus, histone
methylation could be affected by the input of other metabolic pathways to the SAM cycle,
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cellular availability of vitamins and any factors that affect the enzymes in the SAM cycle.
There are a growing number of evidences that support this idea. For example, inhibition
of threonine to SAM decreased the SAM/SAH ratio, H3 K4 methylation and restricted
embryonic stem cell growth and differentiation (64). Histone demethylase LSD family is
FAD-dependent and JmjC family is α-ketoglutarate dependent. These two metabolites
are both closely linked to mitochondria oxidative metabolism and are component of TCA
cycle (65). Alteration in the cellular level of FAD/FADH2 or a-KG affects histone
methylation level, and gene transcription (66). Mutations in metabolic enzymes have been
characterized in human cancer and affect histone methylation and affect cancer growth
and metastasis (67). As metabolic intermediates globally affect enzymatic conjugation or
removal of histone modifications, this mechanism alone is unlikely to achieve gene
specific regulation for metabolic adaptation to a new environment. Hence, a more
sophisticated cellular signaling network accounting for it remains to be characterized for
the transcriptomic reprograming upon metabolic changes.

1.3.2 Studying the dynamics of histone modification.
With the development of next generation sequencing technology, chromatin
immunoprecipitation followed by sequencing (ChIP-seq) method has been widely used
to obtain the genome wide DNA binding site information of any protein of interest (68).
To study how a specific transcription factor or histone modification linked to biological
functions or phenotypes requires the identification of downstream effector genes. ChIP-
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seq is mainly used to understand such regulatory mechanism both globally and gene
specifically. ChIP-seq is performed by capturing protein binding DNA by traditional
ChIP method first, followed by adding oligonucleotide adaptors to those small DNA
fragments for massive parallel sequencing and computational analysis. Cancer cells or
stem cells are known to be heterogenetic, thus the chromatin and transcription status are
distinct in each cells. By utilizing the microfluidic droplet barcoding technology, DNA
fragments from each cells were separated in each droplet and barcoded respectively for
next generation sequencing (69). This technology enabled us to understand the
heterogeneity of human cancers or stem cells and to identify small subpopulations with
unique feature and functional importance.
Classical methods and sequencing technology have built the foundation of
chromatin biology. However, the spatial and temporal resolution of such ‘snapshot’
methods are low to monitor the dynamic and rapid process of transcription initiation,
elongation and termination. Recent advances in fluorescence microscopy and transfection
of single chain antibody facilitate the development of technology that can visualize
chromatin or transcription dynamics at a single site level (70). Single transcription factor
or histone modification tracking within a single cell enabled us to ‘see’ how transcription
factors are recruited by histone modification and assembled at their target sites. Superresolution microscopy based technology enabled us to map the chromatin structures at a
single nucleosome resolution (71). New technologies have helped us to either confirm or
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challenge existing concepts in the chromatin biology field and may put great insights into
the future study.

1.4 Cancer stem cell theory
1.4.1 The basic concept of cancer stem cells
Current concepts suggest that cancers are originated from abnormal genetic or
epigenetic alterations (72). A small portion of cancer cells, displaying the capability of
self-renew and generation of large number of more differentiated form of cancer cells,
are called cancer stem cells (CSCs), which are likely responsible for tumor initiation,
metastasis, relapse and drug resistance(73, 74). Cancer stem cell is initially a hypothesis
proposed to explain the heterogeneity of cancer cells (75). Until mid 1990s, a
subpopulation of leukemia with stem cell like properties was discovered and named
‘cancer stem cells’, mimicking the multipotency and self-renewal properties of adult stem
cells (76). Later, cancer stem cell theory was extended to solid tumors and it has been
identified in almost every cancer types today (77). According to the cancer stem cell
hypothesis, cancer stem cell is capable of forming a new tumor in the immune
compromised animal model, while differentiated cancer cells can not (78). However,
inconsistent results showing that limited number of differentiated cancer cells can also
form tumor in xenograft model have been observed (79, 80). Although this might be due
to the inaccuracy of methodology and the fact that all cancer stem cells must be removed
to eliminate cancer, development of other models may explain those observations and the
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original cancer stem cell theory should be modified. In fact, cancer stem cell is not the
only theory to explain the cancer heterogeneity. Stochastic model and the model
emphasizing the importance of the unique environment of a given cell have also been
proposed (81). Their basic ideas are about that intrinsic genetic or epigenetic variations
or extrinsic microenvironment differences within a group of cancer cells caused the
heterogeneity, which is interchangeable upon changes of intrinsic or extrinsic factors (81).
In the field of tumor initiation, there is increasing support for a non-mutually exclusive
model that combines all above three models to explain the heterogeneity of cancer and
explain the tumorigenicity of differentiated cancer at a given time (82). Although the
cancer stem cell theory is under debate, the study of this interesting subpopulation of cells
remains critical due to its possible drug resistance feature in cancer therapy (83). Cancer
stem cells in many types of cancers are known to be resistant to chemotherapy and
radiation therapy. Treating cancer without taking cancer stem cells into account would
enrich cancer stem cells and exacerbating the malignancy of many cancers (79). Thus the
identification and study the drug resistance mechanism of cancer stem cells become an
urgent task in the cancer stem cell field.

1.4.2 Cancer stem cell markers.
To identify and study cancer stem cells, the methods include the isolation of
specific surface markers or the use of selective culture conditions that prefer the
clonogenicity of cancer stem cells, including in vitro sphere forming assay, in vivo limited
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dilution of xenograft engraftment assay, renal graft assay and etc (84). Live imaging and
in vivo lineage tracking are also important methodology to monitor the self-renewal and
multipotency of cancer stem cells (84). Various biomarkers have been identified for many
cancer types as listed in the table 3. Cancer stem cell markers can be classified into several
categories. The most common one is the cell surface marker category, which is selected
by contrasting the cell surface markers of cancer cells grow under normal and cancer stem
cell enrichment environment. Surface markers facilitate the researchers to use flow
cytometry to analysis the population of cancer stem cells or use fluorescence activated
cell sorting (FACS) or magnetic activated cell sorting (MACS) to isolate putative cancer
stem cells for the functional study (84). The next category is drug resistance markers,
especially include many chemo drug efflux transporters at cell surface to convey the drug
resistant feature of cancer stem cells. However, controversial data showing that drug
resistant markers does not enrich the tumorigenicity of cancer cells in xenograft were
observed in some cancer types (83, 85), suggesting that using markers for drug resistance
alone may not be ideal to distinguish cancer stem cells. Another important category of
markers is the markers for pluripotency. Embryonic stem cell pluripotent factors, like
Oct4, Sox2 and Nanog are important for cancer stem cells, as the embryonic stem cell
gene expression signature was also observed for cancer stem cells in many cancer types
(86). However, the presence of multiple splicing variants of those pluripotent factors
complicated the marker detection, since most of the variants are inactive. Thus, simply
checking transcription activity of pluripotent genes by GFP reporter or protein expression
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level by immunofluorescence staining is not sufficient and it is risky to link such
observations to the the evidence of cancer stem cells. Thus using multiple markers and
functional analysis methods are crucial in studying the cancer stem cells. However, there
are still some limitations of even combining those methods. First, cancer stem cell traits
(markers or functions) may be context specific and depending on the specific tumor
microenvironment, which is different from assay conditions. Moreover, it is not clear
whether cancer stem cells or non-stem cancer cells can be converted mutually. This
plasticity in phenotypes raises serious questions in the validity of marker isolated cancer
stem cells in this field of study (82).
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Breast
ALDH1
BMI-1
CD24
CD44
CD133
CXCR4
DLL4
GLI
Her2
IL-1a
Integrin a6
PTEN

Lung
ABCG2
ALDH1
CD90
CD117
EpCAM

Melanoma
ABCB5
ALDH1
CD20
CD133
Nestin
NGF R

Ovarian
CD24
CD44
CD117
CD133
Ovastacin

Pancreatic
ABCG2
ALDH1
BMI-1
CD24
CD44
CD133
c-Met
CXCR4
PON1

Prostate
ALDH1
BMI-1
CD44
CD151
CD166
Integrin a1, b1
Integrin a6
Trop2

Table 3 List of cancer stem cell markers in various solid tumors (87).
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Accumulating evidences suggested that cancer stem cell markers are not mere
cancer stem cell defining molecules. CD44+ is widely used cancer stem cell markers in
various cancer types, pointing the important role of CD44 in tumors. CD44 is a
transmembrane glycoprotein composed of a conserved extracellular hyaluronan (HA)binding domain, variably spliced regions, transmembrane sequences and intracellular
cytoskeletal-signaling domains (88). One of the interesting areas of research in cancer
stem cells is to study interaction of CD44 with the extracellular matrix HA, which
promotes adhesion, migration and invasion of cancer cells (89). Other studies also found
that HA-bound CD44 interacted with and promotes the receptor downstream kinase
signaling of human epidermal growth factor receptor 2 (HER) (90). HA-bound CD44
activates p300-dependent acetylation of beta-catenin and NF-κB (91). HA-CD44
complex also activates Nanog, which subsequently promotes stem cell factor SOX2 and
drug efflux transporter MDR1 (92). Cancer stem cell marker CD133 is also a
transmembrane glycoprotein, but its biological role is not yet well defined as CD44.
However, the property of the CD133+ cancer cells has been studied and associated to
many stemness factors, drug resistance transporters, receptor tyrosine kinase signaling
and HIF hypoxia related signaling (93).
Aldehyde dehydrogenase (ALDH) activity is another marker widely used in
variety of cancer types. Hematopoietic stem cells display high level of ALDH activity,
mainly through high expression of ALDH1 gene (94). This concept was then adopted in
the cancer stem cell field for many cancer types. ALDH converts retinol to retinoic acid,
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which is important for stem cell differentiation (95). It has also been suggested that
ALDH could mediate the oxidation of many toxic aldehydes, in turn promote the
maintenance of cancer stem cells and possibly drug resistance (95). Similar to the role of
cancer stem cell markers as a cancer stem cell defining molecules, there were
controversial data reported for the function of those cancer stem cell markers in different
cancers types (96), suggesting that the functions of those cancer stem cell markers are
also context dependent.

1.4.3 Signaling pathways involved in the cancer stem cells.
Cancer stem cells have been shown to harbor altered cellular signaling pathways,
especially the pathways that are involved in stem cell self-renew, development and
differentiation, including Wnt/β-catenin, hedgehog, BMP, TGF-β and notch signaling
(97-99). Wnt signaling pathway has been suggested in the maintenance of both normal
stem cells and cancer cells. Wnt binds receptor Frizzled and activates Dvl, in turn
inhibited Axin/APC/GSK3-beta complex mediated beta-catenin turn over and promote
beta-catenin downstream target transcription (100). In the case of cancer stem cells,
inhibition of Wnt signaling results in the increased chemo-sensitivity for the chemo
resistant population of cancer cells and reduced expression of stemness factor OCT4
(101), suggesting a critical role for Wnt in cancer stem cell functions. Notch signaling
pathway determines cell fate probably through its four different Notch isoforms, the
function of which are non-overlapping and/or opposing on differentiation and
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development (102). This fact explains the observation that Notch1/2 in SCLC is tumor
suppressive, but Notch3 is up-regulated in NSCLC (103). ALDH+ population of NSCLC
has been shown to be dependent on Notch activity for clonogenicity (104), indicating a
role of Notch in cancer stem cell function. The hedgehog pathway is a extensively studied
area in developmental and stem cell biology, which regulates stem cell maintenance,
proliferation and differentiation. Hedgehog binds to receptor patched-1 and releases
smoothened protein from the membrane. Activated smoothened further antagonizes Gli
and its downstream target. Deregulated hedgehog pathway results in tumor proliferation
and metastasis (105). It is also reported that Hedgehog pathway promotes mammosphere
formation and cancer initiation through cancer stem cell factor BMI, and pharmacological
inhibition of Hedgehog pathway reduced CD133 or CD44 cell population (106),
indicating its involvement in the maintenance of cancer stem cells. Together, studying
signaling pathways related to cancer stem cells extended our view of cancer development
and may facilitate the drug design for resistant cancer cells.

1.5 Protein ubiquitination and its role in signaling
1.5.1 Basic concepts of ubiquitination
Ubiquitination is a one of the well-studied post-translational modifications that is
critically involved in many cellular processes (107). Basically it is a reaction of covalent
attachment of the ubiquitin protein to the lysine residues on the substrate proteins.
Ubiquitin is a small protein found in eukaryotic and there are four fusion genes in human
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that can produce the precursor of ubiquitin. The ubiquitination process is accomplished
by a cascade of reactions that involves three enzymes, namely E1 ubiquitin-activating
enzyme, E2 ubiquitin-conjugating enzymes and E3 ubiquitin ligase (107). Ubiquitin is
first activated by a ATP dependent two-step reaction by E1. Initially, E1 binds to ATP
and catalyzes the acyl-adenylation of the C-terminus of ubiquitin. Adenylated C-terminus
then forms a thioester bond with the cysteine sulfhydryl group on E1. E2 enzyme
catalyzes a transesterification reaction, which transfers the ubiquitin from E1 to the active
site cysteine of E2. At last step, E3 ligase catalyzes the formation of the isopeptide bond
between a lysine residue of the substrate protein and C-terminus of ubiquitin. Human
cells possess hundreds of E3 ligases to catalyze the ubiquitination of various substrates
(107). E3 ligases generally determine the substrate specificity of the ubiquitination.
HECT domain and RING domain E3 ligases are two basic categories (108). HECT
domain E3 ligase forms a transient binding with ubiquitin, while RING domain E3 ligases
directly transfer ubiquitin from E2 to substrate. Other E3 ligases include Anaphasepromoting complex (APC) and Skp, Cullin, F-box containing complex (SCF), which are
large E3 ligase complexes that recognize substrates and transfer ubiquitin through the
cooperation of different subunits (109).
Ubiquitination chain can range from mono, poly or even multi-mono, multi-poly
ubiquitination, which decide the distinct fate of the substrate proteins (107). Mono
ubiquitination can be involved in protein trafficking, endocytosis and viral budding. The
situation for poly ubiquitination is more complicated. Depending on the linkage residue
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between ubiquitin molecules within poly ubiquitination chain, it can form K6, K11, K27,
K29, K33, K48, K63 and M1 linkage (107). K48 linked poly ubiquitination is the most
well-studied one and its conjugation on protein marks the proteins for proteasomal
degradation. K48 linked ubiquitination is recognized by the 26S proteasome and substrate
proteins are rapidly degraded by proteases inside the proteasome, while ubiquitin chain
is cleaved before this process and recycled for further usage. K63 linked ubiquitination
does not trigger proteasomal degradation, but is involved in the various cellular processes
including endocytosis, inflammation, kinase activation and DNA repair (107). K63 linked
ubiquitination can be recognized by the ubiquitin binding domains, including UIM, UBA,
UBC and etc., allowing that K63 linked ubiquitination to serve as a molecular scaffold to
transduce and amply the cellular signaling (110). Little is know about other types of
linkage, since the observations and functional studies of those linkages are just emerging
and their involvement in cellular processes is largely unclear.

1.5.2 Nedd4 family E3 ligase and their function.
As mentioned above, E3 ligases are mainly categorized into two groups, by either
containing a zinc-binding RING finger E2-binding adaptor domain or a Homologous to
the E6-AP Carboxyl Terminus (HECT) catalytic domain. Nedd4 family E3 ligases
belong to the HECT domain class of E3 ligases. Nedd4 is initially found in a screen for
genes developmentally down regulated in the early embryonic mouse central nervous
system (111). Other E3 ligases with similar structures, which are now Nedd4 family
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members are subsequently found and characterized. They are Nedd4L, ITCH, SMURF1,
SMURF2, WWP1, WWP2, NEDL1 and NEDL2 in human (111). Structurally, they all
contain a HECT domain, a C2 domain and several WW domains on the N terminal for
substrate recognition (111). However, shared molecular structure does not result in a
redundant biological function, since individual knockout of Nedd4 family gene often
exhibits strong phenotypes or even causes embryonic lethality (111). Consistent with the
general concept of E3 ligases, this observation suggests that they may have different
substrate specificity.
Nedd4 activity is regulated by auto-inhibition, where its C2 domain binds to its
HECT domain to form an inhibitory structure (111). This inhibition can be disrupted by
calcium, or phosphorylation of NEDD4 at specific tyrosine residues to activate the E3
ligase activity (112, 113). The WW domains on Nedd4 is required to recognize PY motif
(PPxY) on its substrate, while adaptor proteins NDFIP1 and NDFIP2 can assist the
binding between Nedd4 and it substrates lacking PY motifs (114). The HECT domain on
Nedd4 forms a thioester bond with ubiquitin before it is transferred from Nedd4 to its
substrates. Nedd4 has been shown to ubiquitinate several ion channels and membrane
transporters and receptors, which often leads to endocytosis and proteasomal degradation
of its substrates (115). While the majority of Nedd4 substrates localizing in either
cytoplasm or plasma membrane are identified, its nuclear substrate is less well-defined.
In vivo, Nedd4 deficiency causes embryonic lethality and profound decrease in IGF-1 and
insulin signaling (115-117). Deletion of Nedd4 also leads to a reduction in effector T-
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cells due to the impairment in the conversion of naïve T-Cells to activated T-Cells (118).
Nedd4 is required for the neuronal development, the formation of dendrites in neuron and
neuron muscular junctions and keeping the normal number of motor and axon neurons
(119). Nedd4 has also been shown to poly-ubiquitinate tumor suppressor PTEN and drive
proteosomal degradation of PTEN (120). However, in certain models, Nedd4 seems does
not target PTEN for degradation (121). Although Nedd4 has been reported to be
frequently overexpressed in many cancer types, its decrease is also associated with some
cancers, where Nedd4 suppresses cancer through targeting N-Myc or c-Myc for
degradation (115, 122). However, whether Nedd4 has a role in CSC regulation is not clear.

1.5.3 Rationale and Hypothesis
HATs often reside in larger protein complexes for the gene-specific recruitment
and targeted histone acetylation(37). However, the mechanism underlying the recruitment
of HATs for global histone acetylation is unclear. As depleting subunits recognizing
known motifs or histone modifications in HAT complex did not affect global histone H3
acetylation (123), we speculated that there are other previously unknown H3
modifications, which may be involved in the global recruitment of HATs. By analyzing
the published large-scale quantitative mass spectrometry data sets (124-126), we found
that H3 proteins were ubiquitinated on multiple lysine (K) residues. Interestingly, this
ubiquitination is also induced by glucose, suggesting that H3 ubiquitination may be a
potential prerequisite for HAT recruitment and H3 acetylation upon glucose stimulation.
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Since cancer stem cells represent a therapeutically challenging population of cancer cells,
we also seek to examine whether this glucose induced H3 acetylation and its downstream
target genes are involved in the regulation of cancer stem cells.
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Chapter 2 Materials and Methods
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2.1 Cell culture, glucose treatment, transfection, viral transduction and
reagents.
Hep3b, HEK293T, Du145 cell lines were purchased from ATCC and cultured in
DME/F12 medium (GE Healthcare HyClone) in 10% Fetal bovine serum (FBS, Sigma
Aldrich), Penicillin Streptomycin (Pen Strep) and L-glutamine. WT and Nedd4-/- MEFs
cultured in DMEM medium containing 10% FBS were obtained from Dr. Xinjiang Wang.
For the add-back of glucose procedure, 80% confluent cells were cultured in DMEM
medium without glucose (Invitrogen) for 4 hours and resupplied with glucose (4.5g/L)
for indicated times. 293T cells were transfected by standard calcium phosphate method.
Other cell lines were transfected using Lipofectamine 3000 (Invitrogen) by the
manufacturer’s protocol and if indicated, cultured in medium containing Hygromycin B
(100 ug/mL) to establish stable cell lines. For lentiviral infection, 293T cells were cotransfected with lentiviral plasmid (pLKO-puro), packing plasmid (deltaVPR8.9) and
envelope plasmid (VSV-G). 2 days after transfection, medium containing virus particles
were used to infect mammalian cell lines. All the infected cells were cultured in the
medium containing 2μg/ml puromycin for 1 week before further analysis. Short
interfering RNA (shRNA) for NEDD4, H3.3 and GCN5 were purchased from Sigma
Aldrich. Flag-H3.3 plasmid and lentiviral Flag-H3.3 plasmid were obtained by inserting
human H3.3 open reading frame into pCDNA3.1-hygro or pLKO-as3w-puro vectors
respectively. All H3.3 mutation constructs (K4R, K9R, K14R, K18R, K23R, K27R,
K36R, K37R, K36/37R, K23/36/37R, K56R, K64R, K79R, K115R and K122R) were
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generated by site-directed mutagenic PCR according to the kit manual (Stratagene). Hisubiquitin plasmid was previously described(127). HA-BMI-1 and HA-RNF2 were
obtained from Dr. Shiaw-Yih Lin. HA-NEDD4 and HA-UHRF-1 plasmids were from
Drs. Pier Paolo Pandolfi and Hung-Ying Kao, respectively. HA-CBL-A, HA-CBL-B and
HA-CBL-C were received from Dr. Stanely Lipkowitz. Flag-HA-RNF8 was kindly
provided by Dr. Junjie Chen. V5-NEDD4 WT, Y43/585F and Y43/585E mutant are from
Dr. Daniela Rotin. Flag-NEDD4L, NEDL1 and NEDL2 are from Dr. Wesley Sundquist.
Flag-WWP1 and WWP2 are from Dr. Wenyi Wei. The following antibodies were used
in this study: anti-H3 (Abcam, ab12079), anti-H3 pan-ac (Active Motif, 39139), anti-H3
K4ac (Active Motif, 39381), anti-H3 K9ac (Active Motif, 39917), anti-H3 K14ac (Active
Motif, 39697), anti-H3 K18ac (Active Motif, 39755), anti-H3 K23ac (Active Motif,
39131), anti-H3 K27ac (Active Motif, 39133), anti-H3 K36ac (Active Motif, 39379),
anti-H3 K56ac (Active Motif, 61061), anti-H3 K4me3 (39915), anti-H3 K9me3 (Active
Motif, 39765), anti-H3 K27me3 (Active Motif, 39155), anti-H3 K4me2, K9me2,
K27me2, K36me2, K79me2 (Cell Signaling Technology, 9847), anti-H3s10p (Abcam,
ab5176), anti-H3.3 (EMD Millipore, 09-838), anti-NEDD4 (Novus, NBP1-40112), antiGCN5 (Active Motif, 39975), anti-USP22 (Abcam, ab4812), anti-Flag (Sigma), anti-HA
(Covance), anti-Actin (Sigma), anti-IL1α (Abcam, ab17281), anti-IL1β (Abcam, ab2105)
and anti-IgG heavy chain HRP (Sigma Aldrich, a1949). The following recombinant
proteins were used in this study: active NEDD4 (Millipore), histone octamer (EMD
Millipore), E1 enzyme (Sigma Aldrich), UbcH4 (EMD Millipore), UbcH5a (EMD
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Millipore), UbcH5b (EMD Millipore), UbcH5c (Boston Biochem), UbcH6 (EMD
Millipore), UbcH7 (Boston Biochem), ubiquitin (Boston Biochem), GST-ubiquitin
(Millipore), GCN5 (Novus), IL1β human (Sigma Aldrich). The following chemicals were
used in this study: N-acetyl-L-cysteine (NAC) (Sigma Alrich), N-Ethylmaleimide (NEM)
(Calbiochem) and DCFDA (Invitrogen).

2.2 In vivo ubiquitination assay.
In vivo ubiquitination assay was performed as previously described(127). Briefly, 293T
cells were transfected with his-Ubiquitin and other indicated plasmids for 36 hours and
harvested by denaturing buffer (6 M guanidine-HCl, 0.1 M Na2HPO4/NaH2PO4, 10 mM
imidazole). Ni-NTA Agarose beads (QIAGEN) were incubated with cell lysates for 3.5
h to pull-down his-Ubiquitin and washed beads were analyzed by Western blot.

2.3 In vitro ubiquitination assay.
3ug recombinant histone octamer and 5ug active form of NEDD4 were incubated with
0.5 µg E1 activating enzyme, 1.5 µg Ubiquitin, 0.5 µg various E2 enzymes UBCH4,
UBCH5a, UBCH5b, UBCH5c, UBCH6 or UBCH7 and 2.5 mM ATP in reaction buffer
(1.5 mM MgCl2, 5 mM KCl, 1 mM DTT, 20 mM HEPES (pH7.4)) in a total 20ul reaction
volume at 37°C for 3 hours. Ubiquitination on substrate was then detected by Western
blot analysis.
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2.4 Whole cell extracts for histone modification detection, cellular fractionation,
chromatin fractionation and immunoprecipitation.
Whole cell extracts were prepared by boiling the cell pellets in SDS sample buffers for
10min. Cytosol and nucleus were purified using standard protocol. Briefly, cells were resuspended in hypertonic buffer (10mM Tris pH 7.6, 10mM MgCl2, 0.1% NP-40), then
lysed using Dounce homogenizer and centrifuged at 1000g. Pellets containing nucleus
were washed twice with hypertonic buffer. Supernatant containing cytosol was further
cleared by centrifuging at 12000g. Chromatin fractionation was performed as
described(128). Briefly, cells were first lysed with buffer A (50 mM Hepes, pH 7.9, 10
mM KCl, 1.5 mM MgCl2, 0.34 M Sucrose, 10% Glycerol, 1 mM DTT, 0.1% Triton X100, NEM, protease inhibitor cocktail (Biotool) and phosphatase inhibitor cocktail
(Biotool)) on ice for 30 min. After centrifuge at 1000g, pellets including the nucleus were
further lysed with buffer B [3 mM EDTA, 0.2 mM EGTA, 1 mM DTT, NEM, protease
inhibitor cocktail (Biotool) and phosphatase inhibitor cocktail (Biotool)]. After centrifuge,
pellets containing the chromatin were washed, and sonicated in SDS sample buffer for
Western blot analysis. To immunoprecipitate proteins, cells were lysed and sonicated in
RIPA buffer (50mM Tris pH 7.4, 150mM NaCl, 0.1% SDS, 0.5% Sodium Deoxycholate,
1% NP-40, 1mM EDTA, protease inhibitor cocktail (Biotool), phosphatase inhibitor
cocktail (Biotool) and NEM). Cell lysates were incubated at 4°C with antibody overnight
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and agarose protein A/G beads for 3 hours, and then beads were washed with RIPA buffer
for 5 times before eluting with SDS sample buffer.

2.5 Endogenous ubiquitination assay.
Briefly, cells were collected and boiled in SDS lysis buffer (2% SDS, 150 mM NaCl, 50
mM Tris-HCl, pH 7.4, protease inhibitor cocktail) for 10 min. Lysate was sonicated and
diluted 10 times with dilution buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM
EDTA, 0.5% Sodium Deoxycholate, 1% NP-40, protease inhibitor cocktail and NEM).
Samples were then incubated on ice for 30 min and cleared by centrifuging.
Immunoprecipitation assay using anti-Ub (FK2) antibody was performed as described
above and H3 ubiquitination was detected by Western blot using anti-H3 antibody.

2.6 Chromatin immunoprecipitation followed by qPCR (ChIP-qPCR) assay.
ChIP assay was performed as described(129) with some modifications. Cells were crosslinked in culture media (with 1% formaldehyde) with gentle shaking for 10min at room
temperature and stopped by adding glycine to a final concentration of 0.125 M. Cells
were washed with PBS three times and nuclei were isolated. Nuclei were then lysed in
RIPA buffer with proteinase inhibitor cocktails and sonicated using Bioruptor to shear
genomic DNA to a range of 200-1000 bps. Lysates were cleared and blocked with BSA
(final concentration of 1mg/mL) and salmon sperm DNA (final concentration of
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0.3mg/mL). Pre-cleaned lysates were immunoprecipitated with various antibodies,
followed by adding protein A/G beads. Beads were washed and eluted by 400uL elution
buffer (with 0.1 M NaHCO3, 1% SDS). The DNA was directly recovered by gel extraction
kit (Omega) and analyzed by real-time qPCR.

2.7 Chromatin immunoprecipitation followed by sequencing (ChIP-seq).
Chromatin immunoprecipitation assay was performed using ChIP-IT High Sensitivity kit
(Active motif) according to the manufacturer’s manual. The Illumina compatible libraries
were prepared using DNA Library preparation kit (KAPA, KK8232), as per the
manufacturer’s protocol. In brief, DNA was fragmented to a median size of 150bp by
sonication. Fragmented DNA ends were polished and 5′-phosphorylated. After addition
of 3′-A to the ends, indexed Y-adapters were ligated and the samples were PCR amplified.
The resulting DNA libraries were quantified and validated by qPCR, and sequenced on
Illumina’s HiSeq 2000 in a single-read format for 36 cycles. The resulting BCL files
containing the sequence data were converted into “.fastq.gz” files and individual sample
libraries were demultiplexed using CASAVA 1.8.2 with no mismatches.

2.8 ChIP-seq data analysis.
Briefly, 36 nucleotides (nts) sequencing data (.fastq.gz) were unachieved and imported
to local galaxy project instance(130-132). Sequences for each sample were concatenated
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and 3nts from both 5’ and 3’ end were trimmed off. The processed data were aligned to
the hg19 (human) assembly using Bowtie2(133). For each sample, the ChIP-seq peak
profiles were obtained by normalizing ChIP data to input data (mappable reads were
normalized to 1X genome coverage of hg19) using BamCompare tool in DeepTools(134).
The data were visualized by preparing custom track hubs on the UCSC genome browser.
Global average profiles at TSS or enhancer regions were calculated by ComputeMatrix
tool in DeepTools(134) and visualized by Microsoft Excel. Known enhancer regions were
defined according to Broad ChromHMM tracks for HepG2 cells. Differential ChIP-seq
peaks between samples were identified by Diffreps using G-test(135). Genes, the TSS of
which was located within differential peaks, were then listed for subsequent Venn
diagram visualization. Reviewer private access link for ChIP-seq data:
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=apehcoywnhsjxcr&acc=GSE663
40

2.9 RNA extraction and cDNA synthesis.
Cells were lysed in TRIZOL reagent (Invitrogen) and extracted by chloroform. Total
RNA were then precipitated by isopropanol and washed with 70% ethanol. cDNA were
synthesized according to the standard M-MLV reverse transcriptase protocol. Briefly,
total RNA were mixed with oligo(dT), dNTP, M-MLV reverse transcriptase (Invitrogen)
in the M-MLV buffer and the reaction was performed using a thermo cycler.
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2.10 Microarray, Gene set enrichment analysis (GSEA) and TCGA data
analysis.
Total RNA was extracted and purified using RNeasy mini kit (QIAGEN) according to
manufacturer’s manual. Microarray analysis was performed for total RNA on Illumina
HumanHT12v4 platform following Illumina’s standard procedure. All data sets were
normalized based on the mean value, and differentially expressed genes were ranked by
T-test. Gene set enrichment analysis was performed using GSEA software with KEGG
pathway gene sets and GO term pathway gene sets respectively. Significantly enriched
gene sets (p<0.05, q<0.25) were visualized using Cytoscape(136). TCGA exon
expression data sets (Illumina) for various cancer types were visualized in UCSC cancer
genome browser. Cases with highest and lowest 30% expression of NEDD4 were
included to evaluate the correlation between the expression of NEDD4 and other genes
by Wilcoxon test (Bonferroni correction). Exons show significant (p<0.05) correlations
with NEDD4 expression were shown either in red (positive correlation) or green
(Negative correlation) in the histogram. Reviewer private access link for microarray data:
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=evazwqokhlgtbwl&acc=GSE663
41
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2.11 In vitro binding and native gel analysis.
Recombinant full-length GCN5 and ubiquitin were mixed in the binding buffer (25 mM
HEPES, pH 7.4, 125 mM KCl, 5 mM MgCl2, 0.5 mM EDTA, 0.5% Triton X-100) and
incubated on ice for 30min. Samples were then mixed with sample buffer (62.5 mM
Tris-HCl pH6.8, 25% glycerol, 1% Bromophenol blue) or SDS sample buffer, and then
separated by native Polyacrylamide gel electrophoresis (PAGE) or SDS-PAGE
respectively. GCN5 and ubiquitin proteins were then detected by Western blot.

2.12 In vitro tumor sphere formation and in vivo tumor engraftment assay.
For in vitro tumor sphere forming assay, 5000 cells were seeded in the ultra-low
attachment 6-well plate (Corning Life Science) and cultured in tumor sphere forming
medium (DME/F12 supplemented with 5ug/mL Insulin, 0.05ug/mL hEGF and 0.5ug/mL
Hydrocortisone). Cells were incubated at 37 °C for 13 days and spheres larger than 100um
were counted. For in vivo tumor engraftment assay, cancer cells were first stained using
ALDEFLUOR Kit (StemCell Technology) following manufacturer’s manual. Cells with
top 2.5% Aldh enzymatic activity were then isolated by cell sorting using flow cytometry.
1000 isolated cells were subcutaneously injected into each nude mouse (NCRNUF/Homozygous, Taconic Farms) and monitored for tumor growth for 70 days. Mice died
tumor free were excluded from final results.
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2.13 ROS and GSH detection.
To detect cellular ROS, cells were collected and incubated with DCFDA at 37°C for
30min and then subjected to flow cytometry analysis. ROS levels were calculated as the
mean fluorescence signal. Cellular GSH level was determined by Glutathione assay kit
(Sigma Aldrich, CS0260).
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Chapter 3 Results
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3.1 NEDD4 ubiquitinates H3 upon glucose stimulation
By analyzing the published large-scale quantitative mass spectrometry data sets
(124-126), we found that H3 proteins were ubiquitinated on multiple lysine (K) residues
(Figure 1a). While these proteomic studies are mostly carried out under non-stimulus
conditions, it is critical to know which physiological cues can drive this ubiquitination
modification and what functions it may play. To address these questions, we challenged
cells with various physiological stimuli and performed in vivo ubiquitination assay to
detect ubiquitination of endogenous H3 proteins. Of these stimuli, H3 ubiquitination was
drastically inhibited by glucose deprivation, but only slightly affected under glutamine
deprivation or remained unaltered by other stresses, such as serum starvation, genotoxic
stress and oxidative stress (Figure 1b and 1c). We also excluded the possibility that
glucose starvation causes irreversible damages to the cells, thereby leading to the
reduction of H3 ubiquitination indirectly, as add-back of glucose to cells under glucose
deprivation readily recovered H3 ubiquitination (Figure 1d and 1e). Accordingly, these
results suggest that glucose is a bona fide physiological activator for H3 ubiquitination.
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Figure 1 Glucose induces H3 ubiquitination.

a. Summary of H3 ubiquitination sites identified in various large-scale quantitative
proteomics studies.
b, c. Glucose deprivation abolished H3 ubiquitination. 293T cells were transfected with
his-ubiquitin plasmid (His-Ub) for 36 hours and treated with various stresses for 4 hours
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before in vivo ubiquitination assay to access the H3 ubiquitination (See experimental
procedures for details).
d. Feeding glucose recovered H3 ubiquitination. 293T cells were transfected with hisubiquitin plasmid for 36 hours, then glucose-starved for 4 hours, and added-back glucose
for indicated times before in vivo ubiquitination assay.
e. Glucose induces H3 ubiquitination in a time dependent manner. Hep3B cells were
glucose starved for 4 hours and glucose was added for indicated time before chromatin
fractionation assay.
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We next determined which E3 ligase is responsible for glucose-induced H3
ubiquitination. By screening a panel of ubiquitin E3 ligases, NEDD4 (also known as
neural precursor cell expressed developmentally down-regulated protein 4) was identified
to be a potential E3 ligase for H3 ubiquitination, as wild-type (WT) NEDD4 could
promote H3 ubiquitination, but not E3 ligase dead mutant NEDD4 (NEDD4-CS), (Figure
2a to 2c). In line with this possibility, NEDD4 knockdown abolished H3 ubiquitination
(Figure 2d). To investigate whether NEDD4 is a direct E3 ligase for H3, we performed
in vitro ubiquitination assay by mixing recombinant active form of NEDD4 with various
E2 ubiquitin-conjugating enzymes and histone octamer. We found that NEDD4 in
combination with UbcH7 effectively triggered in vitro H3 ubiquitination, although
UbcH5 a/b/c mix or UbcH6 also exhibited enzymatic activity (Figure 2e).
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Figure 2 Nedd4 is the E3 ligase for H3.

a, b. Screening of E3 ligases for H3 ubiquitination. 293T cells were transfected with hisubiquitin plasmid and various E3 ligases constructs for in vivo ubiquitination assay.
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c. NEDD4 E3 ligase dead mutant (CS mutant) failed to trigger H3 ubiquitination. 293T
cells were transfected with his-ubiquitin plasmid and WT NEDD4 or NEDD4 CS mutant
construct for in vivo ubiquitination assay.
d. NEDD4 knockdown abolished H3 ubiquitination. Control and NEDD4 knockdown
293T cells were transfected with his-ubiquitin plasmid for in vivo ubiquitination assay.
e. NEDD4 ubiquitinated H3 in vitro. In vitro ubiquitination assay was performed for
recombinant NEDD4 and histone octamer (See experimental procedures for details).
Reaction products were then assessed by Western blot using anti H3 antibody. H3 monoand di-ubiquitination have predicted molecular weights of ~25kDa and ~33kDa. S.E. and
L.E. are short for shorter exposure time and longer exposure time respectively.
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Next we investigated whether NEDD4 is required for glucose-induced H3
ubiquitination. By performing endogenous ubiquitination assay, we found that NEDD4
knockdown or knockout abolished endogenous H3 ubiquitination induced by glucose
treatment (Figure 3a and 3b), indicating a physiological role of NEDD4 in mediating
glucose-induced H3 ubiquitination. We further asked the question whether the glucose
levels could orchestrate E3 ligase activity of NEDD4. Our data showed that NEDD4
overexpression failed to trigger H3 ubiquitination under glucose deprivation, whereas
add-back of glucose readily rescued NEDD4 overexpression induced H3 ubiquitination
(Figure 3c). As we have also noticed that H3 ubiquitination in some of our experiments
displayed multiple ubiquitination bands at higher molecular weight, we sought to test
whether H3 undergoes poly-ubiquitination or multi-mono-ubiquitination. We found that
ubiquitin with its all K mutated to R (Ub K0) did not affect H3 ubiquitination pattern in
the in vivo ubiquitination assay (Figure 3d), indicating that NEDD4 mono-ubiquitinates
H3 at multiple sites. Moreover, while NEDD4 is previously shown to regulate protein
mostly in the cytosol and plasma membrane, a few nuclear substrates for NEDD4 are
found(137, 138). Consistently, we found that NEDD4 could be detected both in cytosol
and nucleus by using biochemical fractionation and immunofluorescence assays (Figure
3e and 3f), suggesting that NEDD4 can target its protein substrates in the nucleus such as
H3. Collectively, these data provide strong evidence that NEDD4 is a direct E3 ligase and
responsible for glucose-induced H3 ubiquitination.
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Figure 3 Glucose induced H3 ubiquitination is Nedd4 dependent.

a, b. NEDD4 knockdown or knockout abolished glucose-induced H3 ubiquitination.
Hep3B cells were glucose starved for 4 hours and added-back glucose for 2 hours before
endogenous ubiquitination assay (see experimental procedures for details). H3
ubiquitination was then visualized by Western blot.
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c. Add-back of glucose recovered NEDD4 overexpression induced H3 ubiquitination.
293T cells were transfected with his-ubiquitin and NEDD4 plasmids for 36 hours, then
glucose-starved for 4 hours, and added-back glucose for indicated times before in vivo
ubiquitination assay.
d. NEDD4 triggered mono-ubiquitination on H3. 293T cells were transfected with FlagH3, HA-NEDD4, His-Ub WT and His-Ub K0 as indicated before in vivo ubiquitination
assay.
e. Cellular fractionation was performed for control and NEDD4 knockdown Hep3B cells.
f. Immunofluorescence assay was performed for Hep3B cells. The intensity of NEDD4
staining (Green) and DAPI staining (Blue) along the yellow line in the image was shown
in the histogram.
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To understand how glucose promoted NEDD4 mediated H3 ubiquitination, we
speculated that glucose treatment might activate NEDD4 through altering the posttranslational modification status of NEDD4. As glucose treatment could elevate the
cellular level of ATP and acetyl-CoA, which are important cofactors for protein
phosphorylation and acetylation, we evaluated overall phosphorylation and acetylation of
NEDD4 protein. Interestingly, we found that tyrosine phosphorylation of NEDD4, but
not NEDD4 serine/threonine and acetylation, is strongly induced by glucose treatment
(Figure 4a). As a previous report shown that growth factor mediated NEDD4
phosphorylation at tyrosine (Y) 43 and Y585 promotes NEDD4 E3 ligase activity (112),
we examined whether glucose also induced NEDD4 phosphorylation at tyrosine (Y) 43
and Y585 and found that mutating Y43/585 to phenylalanine (F) blocked glucose induced
NEDD4 tyrosine phosphorylation (Figure 4b), indicating that glucose induces NEDD4
tyrosine phosphorylation at Y43 and Y585, which may then activate NEDD4 through
Y43/585 phosphorylation. In support of this notion, NEDD4 Y43/585F mutant failed to
trigger H3 ubiquitination, but phosphorylation mimetic mutant Y43/585E enhanced H3
ubiquitination more efficiently than WT NEDD4 (Figure 4c). Importantly, Y43/585E
mutant rescued H3 ubiquitination under glucose deprivation to the level similar to that
triggered by WT NEDD4 in glucose-stimulated conditions (Figure 4d). Collectively, our
results suggest that glucose induces NEDD4 activation by inducing NEDD4 tyrosine
phosphorylation at Y43 ad Y585, in turn leading to H3 ubiquitination.
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Figure 4 Glucose induces the tyrosine phosphorylation of Nedd4.

a. 293T cells transfected with HA-NEDD4 was treated with glucose and harvested for
immunoprecipitation assay.
b. Glucose induced NEDD4 phosphorylation at Y43 and Y585. 293T cells transfected
with WT or Y43/585F NEDD4 plasmids were treated with glucose and harvested for IP.
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c. NEDD4 phosphorylation is required for H3 ubiquitination. 293T cells transfected with
WT, Y43585F or Y43/585E NEDD4 plasmids were harvested for in vivo ubiquitination
assay.
d. 293T cells were transfected with His-Ub and indicated plasmids and treated with
glucose before in vivo ubiquitination assay.
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3.2 Glucose-induced H3 K23/36/37 ubiquitination by NEDD4 is required for
H3 K9 and K14 acetylation
Next we determined whether NEDD4 mediated H3 ubiquitination regulates H3
acetylation. Similar to H3 ubiquitination, we found that glucose treatment readily induced
H3 acetylation on K9, K14, K27 and K56 sites, but had no effect on H3 phosphorylation,
H3 di- and tri-methylation or H3 acetylation at other lysine sites (Figure 5a to 5e). Notably,
NEDD4 knockdown or knockout specifically impaired glucose-induced H3 acetylation,
but not other H3 modifications (Figure 5a to 5e), suggesting that there is a link between
H3 ubiquitination and H3 acetylation under glucose stimulation.
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Figure 5 Nedd4 is required for glucose induced H3 acetylation.
a. NEDD4 knockdown abolished glucose-induced H3 K9, K14, K27 and K56 acetylation.
Control and NEDD4 knockdown Hep3B cells were glucose-starved for 4 hours, and
added-back glucose for 3 hours before whole cell extraction for Western blot analysis
(See experimental procedures for details). A. E. is short for acid extraction.
b, c. Quantification of Western blot data (n=3, mean ± S.D.).
d, e. NEDD4 deficient iMEF cells or MDA231 cells were treated with glucose and
harvested for Western blot analysis.
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While mammalian H3 contains three isoforms (H3.1, H3.2 and H3.3), H3.3 is
found to be the major isoform decorated by H3 acetylation(139). Consistent with the
previous findings, we demonstrated that H3.3 knockdown abolished H3 acetylation on
K4, K9, K14, K23, K27 and K56, but not K18 and K36 (Figure 6a). Similar to NEDD4
knockdown and glucose stimulation, H3.3 knockdown also did not alter H3 methylation
(Figure 6a). We then used H3.3 to determine NEDD4 dependent ubiquitination sites on
H3. After serial mutagenesis on all H3.3 lysine residues, we found that mutation of K23
or K36/37 effectively blocked glucose- and NEDD4-mediated H3.3 ubiquitination
(Figure 6b to 6d), suggesting that NEDD4 specifically ubiquitinates H3 on K23, K36 and
K37 residues. The existence of endogenous ubiquitination modification on these sites was
also supported by previous large-scale quantitative mass spectrometry analysis(125, 126).
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Figure 6 Nedd4 ubiquitinates H3 at K23/36/37 residues.
a. H3.3 knockdown abolished H3 K9, K14, K27 and K56 acetylation. Control and H3.3
knockdown Hep3B cells were lysed for Western blot analysis.
b. H3 K23R and K36/37R mutant abolished glucose induced H3 ubiquitination. Hep3B
cells expressing various Flag-H3.3 constructs were glucose-starved for 4 hours and
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added-back glucose for 2 hours before chromatin fractionation assay. Ubiquitination
levels were normalized to input (n=5, mean ± S.E.M.). N.S. is short for non-specific band.
c. H3 K23 and K36/37R mutant abolished NEDD4 overexpression induced H3
ubiquitination. 293T cells were transfected with his-ubiquitin, NEDD4 plasmids and
various Flag-H3.3 constructs for 36 hours before in vivo ubiquitination assay.
Ubiquitination levels were normalized to input.
d. Chromatin fractionation was performed for Hep3B cells stably expressing Flag-H3.3
WT or K23/36/37R. NEM was added to preserve ubiquitination.
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To determine the causal relationship between H3 ubiquitination and acetylation,
we stably expressed WT H3.3 and H3.3 ubiquitination-deficient mutant in Hep3b cells to
examine H3 acetylation. Consistent with the effect of glucose and NEDD4 on H3
acetylation, H3.3 K23/36/37R mutant displayed impaired H3 acetylation on K9 and K14
(Figure 7a to 7d), while single or double mutation also displayed partial effect on H3
acetylation (Figure 7e).
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Figure 7 H3 ubiquitination is required for H3 acetylation.
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a, b. H3 K23/36/37R is defect in H3 K9/K14 acetylation. WT or K23/36/37R FlagH3.3 was stably expressed in Hep3B cells and immunoprecipitated for Western blot
analysis.
c, d. Quantification of Western blot data (n=3, mean ± S.D.).
e. Various mutants of Flag-H3.3 were restored in shH3.3 Hep3B cells.
Immunoprecipitation assay was used to access the H3 K9ac.
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Additionally, we performed a kinetic study for H3 ubiquitination and K9
acetylation to further elucidate their regulation. Adding back glucose readily induced H3
ubiquitination within 1 hour, while acetylation of H3 at K9 occurred around 2 hours
(Figure 8a), indicating H3 ubiquitination occurs earlier than H3 K9 acetylation and could
be upstream of H3 acetylation. To test whether NEDD4 tyrosine phosphorylation at Y43
and Y583 plays a critical role in H3 acetylation, we restored NEDD4 WT, Y43/585F and
Y43/585E mutant in the NEDD4 knockdown cells to examine their effect on H3
acetylation. We found that NEDD4 Y43/585F mutant failed to rescue glucose induced
H3 K9 acetylation, but NEDD4 Y43/585E mutant fully rescued glucose-induced H3 K9
acetylation and executed such effect even more efficiently than NEDD4 WT (Figure 8b),
confirming that glucose activated NEDD4 through NEDD4 tyrosine phosphorylation.
Taken together, our data suggest that glucose-induced H3 ubiquitination by NEDD4
selectively regulates H3 acetylation.
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Figure 8 Nedd4 activity is important for H3 acetylation.
a. Hep3B cells treated with glucose for various times were harvested for
immunoprecipitation assay. Kinetics of H3 ubiquitination and K9ac were shown in log
scale.
b. NEDD4 knockdown Hep3B cells transfected with WT, Y43/585E or Y43/585F
mutant were treated with glucose and harvested for Western blot analysis.
As Acetyl-CoA, which is a downstream metabolite of glucose, is important for
glucose induced H3 acetylation(60), we then asked which downstream metabolite or
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whether glucose per se is critical for NEDD4 mediated H3 ubiquitination. We treated
cells with ATP, pyruvate or NADH, which can be uptake by cells, and found that none
of them can rescue the impact of glucose deprivation on H3 ubiquitination, H3 K9
acetylation and NEDD4 phosphorylation (Figure 9a and 9b), indicating that metabolites
upstream of pyruvate or glucose per se may promote NEDD4 phosphorylation and
activity through an unknown mechanism. Given the fact that acetyl-CoA is crucial for H3
acetylation and pyruvate can be converted to acetyl-CoA, our surprising observation that
pyruvate cannot fully activate H3 K9 acetylation further demonstrated the necessity of
H3 ubiquitination to trigger glucose-induced H3 acetylation (Figure 9a). Of note, ATP
(or pyruvate/NADH, which can also generate ATP) could partially enhance H3
ubiquitination but not NEDD4 phosphorylation (Figure 9b), suggesting that this ATP
dependent ubiquitination reaction may also be highly sensitive to cellular ATP level. In
line with this observation, glucose treatment, which can strongly induce cellular ATP
level, further enhances H3 ubiquitination triggered by active NEDD4 Y43/585E mutant
(Figure 4d), implying that both ATP level and E3 ligase activity of NEDD4 could regulate
H3 ubiquitination. However, without Acetyl-CoA generated by glucose, ATP, NADH or
active NEDD4 mutant alone could not rescue H3 acetylation (Figure 9a). These results
collectively depict a previously unexpected model of glucose action, which regulates H3
acetylation through not only acetyl-CoA, but also H3 ubiquitination driven by glucose
mediated ATP production and NEDD4 activation.
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a. 293T cells transfected with his-Ub and treated with various metabolites were harvested
for in vivo ubiquitination assay.
b. 293T cells treated with various metabolites were harvested for immunoprecipitation
assay.
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3.3 NEDD4 is required for glucose-induced H3 K9 acetylation at TSS and
enhancers
H3 K9 acetylation is known to localize at the TSS and generally regulates gene
transcription in mammalian cells(140). Having shown that glucose treatment increases
total or cellular level of H3 K9 acetylation in a NEDD4 dependent manner, we asked
whether this process is gene-specific. Therefore, genome-wide pattern of H3K9
acetylation was determined by ChIP-seq assay. Consistent with Western blot result, we
found that glucose globally enhanced H3 K9 acetylation at TSS of genes and such effect
was impaired upon NEDD4 knockdown by ChIP-seq assay (Figure 10a). Our results also
indicated that glucose specifically induces H3 K9 acetylation at TSS of around 2000
genes, and 40% of those acetylation events were NEDD4 dependent (Figure 10b and 10c),
highlighting the critical role of NEDD4 in glucose-induced H3 K9 acetylation at TSS.
Meta-analysis also revealed that glucose promoted H3 K9 acetylation on known
enhancers, and this event was also NEDD4-dependent (Figure 10d), suggesting that
NEDD4 may also participate in the activation of enhancers in response to glucose
stimulation. Together, these data provide further evidence to support that NEDD4
regulates glucose-induced H3 K9 acetylation at TSS and enhancers.
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3.4 Glucose-induced H3 ubiquitination by NEDD4 regulates gene transcription
We next determined whether glucose-induced H3 ubiquitination by NEDD4
regulates transcription, and if so, whether NEDD4 regulates gene transcription through
H3 K9 acetylation. To this end, genome-wide differential gene expression pattern was
determined by gene expression microarray. Integrative analysis of microarray and ChIPseq data sets revealed that NEDD4 knockdown caused down-regulation of around 5,000
genes, and 50% of these genes showed reduced H3 K9 acetylation at TSS upon NEDD4
knockdown (Figure 11a and 11b). Additionally, we applied GSEA (141, 142) (gene set
enrichment analysis) using modified Kolmogorov–Smirnov (K-S) test to evaluate the
statistical relationship between H3 K9 acetylation and gene expression regulated by
NEDD4. The K-S test showed a significant positive correlation (P<0.05) between
NEDD4-dependent H3 K9 acetylation at TSS and NEDD4-regulated gene transcription
(Figure 11c), suggesting that NEDD4 orchestrates gene transcription by regulating H3
K9 acetylation at TSS. We then used qPCR to validate the expression of top list genes
from microarray and showed that NEDD4 deficiency indeed inhibited their expression
(Figure 11d and 11e).

71

a H3K9ac down in NEDD4 KD

Expression down
in NEDD4 KD

b

d
H3K9ac
down in
NEDD4 KD

5062

2488

2511

IL1B
WASF3
IL1A
LYN
CCND2
LTBR
BMP6
RAB31
EHD4
PMM2
GTF2H4
GCLM
GPD1L
ABCA1
CDS1
STAT3
LAMC1
MTHFD1L
MARS
ASNS
SNCA
GTF2E1
CHD8
PAK6
NME4
ACTA2
UBE2E2
ZCCHC7
PDSS1
PRUNE
STK4
FLOT1
DDIT4
LAMB1
ITGAE
TNFRSF1A
MYO10
RIPK2
GALNTL4
ADCY3
TNFRSF21
VPS37B
GMPS
OCRL
CAV2
CAV1
GNG4
KARS
ACACA
SERPINE1

50%

Expression down
in NEDD4 KD

c

Enrichment score

Enrichment score

GSEA using differential K9ac peaks (fold>2)
0.50

0.30

0.25
0.00

0.15

FWER p=0.035
FDR q=0.103

FWER p=0.025
FDR q=0.058

0.00

Ranked by significance

Ranked by fold change

e

-2
1.6
1.4
1.2
1
0.8
0.6
0.4
0.2
0

shLuc

wasf3

LYN

acta2

shNedd4 #1

CCND2

stat3

RAET1L
LY96
CTBP2
TJ P3
CBR3
DDIT3
CCL26
PLAU
ULBP2
HIST2H2AA4
AKR1C3
HMGCS1
TM7SF2
LPCAT1
HIST1H2BC
SNF8
GCNT3
HIST2H2AC
CLCA2
RAB5B
AKR1C2
LAMB3
LAPTM4A
CCL5
NCF2
HIST1H2AC
PRODH
CLDN1
DUSP10
PLAUR
HIST1H4H
AKR1C4
CD55
FUCA1
PFKFB3
AP1M2
MMP1
HIST1H2BD
KYNU
CAPN1
HIST2H2AA3
TNFSF9
NEU1
CDA
STX3
HIST1H2BK
ACSS2
ID3
TDG
ID2

2

shNedd4 #2

stk4

lamc1

chd8

MARS

Figure 11Nedd4 mediated H3 acetylation is required for gene expression.
a-c. NEDD4 regulates H3 K9ac at TSS of NEDD4 target genes. Shown were Venn
diagram of genes with differential expression or differential H3 K9ac at TSS. GSEA was
performed to evaluate the distribution of genes that show down-regulation of H3K9ac at
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TSS in NEDD4 knockdown cells in microarray-derived gene list, which is rank ordered
either by T-test or fold change.
d. Heat map view of top and bottom gene list of microarray data sets. Microarray analysis
for total RNA was performed for control and NEDD4 knockdown Hep3B cells.
e. qPCR was performed to analyze the mRNA level in NEDD4 deficient iMEFs or Hep3B
cells (n=3, mean ± S.E.M.).
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Among those tested genes, IL1α, IL1β and GCLM were most affected and
regulated by glucose (Figure 12a to 12c). ChIP-seq assay revealed that H3 K9 acetylation
at TSS of IL1α, IL1β and GCLM was induced by glucose in a NEDD4-dependent manner
(Figure 12d and 12i). Consistently, ChIP-qPCR analysis confirmed this result in both
NEDD4 knockdown and Nedd4-/- MEFs (Figure 11e to 11g). In addition, we found that
RNA polymerase II binding at TSS of IL1α and IL1β was induced by glucose in a
NEDD4-dependent manner (Figure 11h). As H3.3 ubiquitination affects H3 K9/K14
acetylation, we determined whether H3.3 and its ubiquitination are required for the
transcription of IL1α, IL1β and GCLM.
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Figure 12 IL1A, IL1B and GCLM are glucose inducible target genes of Nedd4.
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+
shNEDD4

a. NEDD4 knockdown impaired IL1α, IL1β and GCLM expression. qPCR was
performed to analyze the mRNA level in control and NEDD4 knockdown Hep3B cells
(n=3, mean ± S.E.M.).
b. IL1α, IL1β and GCLM were induced by glucose. Hep3B cells were glucose-starved
for 4 hours and added-back glucose for 6 hours before qPCR analysis (n=3, mean ±
S.E.M.).
c. qPCR was performed to analyze the mRNA level in NEDD4 deficient iMEFs or Hep3B
cells (n=3, mean ± S.E.M.).
d. UCSC genome browser view of ChIP-seq H3 K9ac signals along IL1B gene.
e. NEDD4 knockdown impaired H3 K9ac at TSS of IL1a IL1b and GCLM genes.
ChIP-qPCR using anti-H3 K9ac antibody was performed for control and NEDD4
knockdown Hep3B cells (n=3, mean ± S.E.M.).
f. H3 K9ac was induced at TSS of IL1 a IL1b and GCLM genes by glucose. Hep3B
cells were glucose-starved for 4 hours and added-back glucose for 6 hours before ChIPqPCR analysis using anti-H3 K9ac antibody (n=3, mean ± S.E.M.).
g. ChIP-qPCR was performed for WT and Nedd4-/- iMEFs.
h. NEDD4 knockdown impaired glucose-induced polymerase II (pol II) binding at TSS
of IL1Aand IL1B genes. Control and NEDD4 knockdown Hep3B cells were glucosestarved for 4 hours and added-back glucose for 6 hours before ChIP-qPCR analysis using
anti-pol II antibody (n=3, mean ± S.E.M.).
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i. UCSC genome browser view of ChIP-seq H3 K9ac signals along IL1A and GCLM
genes.
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Knockdown of H3.3 decreased the mRNA level of IL1α, IL1β and GCLM (Figure
13a), and such defects could be rescued by the restoration of WT H3.3, but not H3.3
K23/36/37R mutants (Figure 13b to 13d). We also found that restoration of single or
double mutations of H3.3 partially rescued gene expression (Figure 13e and 13f). There
data underpin the function of H3 ubiquitination by NEDD4 in transcription activation.
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a. H3.3 knockdown impaired IL1α, IL1β and GCLM expression. qPCR was performed
to analyze the mRNA level in control and H3.3 knockdown Hep3B cells (n=3, mean ±
S.E.M.).
b. H3 ubiquitination deficiency impaired IL1α, IL1β and GCLM expression. qPCR was
performed to analyze the mRNA level in vector, H3.3 WT and H3.3 K23/36/37R mutant
restored H3.3 knockdown Hep3B cells (n=3, mean ± S.E.M.).
c, d. Shown are Flag-H3.3 WT and K23/36/37R restoration efficiency (a) and chromatin
integration efficiency (b) in H3.3 knockdown Hep3B cells.
e, f. qPCR was used to analyze IL1a and IL1b mRNA level in Hep3B cells restored with
various H3.3 constructs.

80

3.5 H3 ubiquitination specifically recruits GCN5 for H3 acetylation
To decipher the underlying mechanism by which H3 ubiquitination regulates H3
acetylation, we determined whether H3 ubiquitination is crucial for the recruitment of
chromatin remodeling complexes containing acetyltransferase activity. By analyzing
microarray data sets against published ChIP-seq tracks for various chromatin binding
factors(143), we identified GCN5, a histone acetyltransferase that preferentially
catalyzes H3 K9 and K14 acetylation in mammalian cells, may be a potential candidate
to mediate the unidirectional crosstalk between H3 ubiquitination and acetylation
(Figure 14a). We then provided a series of experimental evidence to further confirm this
notion. First, we found that the mRNA level of IL1α, IL1β and GCLM was reduced
upon GCN5 knockdown (Figure 14b), similar to the effect of glucose deprivation,
NEDD4 knockdown and H3 ubiquitination deficiency. Second, knockdown of GCN5
selectively impaired H3 acetylation on K9, K14, K27 and K56 (Figure 14c to 14e), but
failed to affect H3 acetylation on other sites and H3 methylation, phenocopying the
effect of NEDD4 knockdown.
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Figure 14 Gcn5 is the potential HAT regulated by Nedd4.
a. GCN5 is predicted as one of the potential regulator for NEDD4 target genes. Top 5000
up-regulated genes from microarray data sets in Fig. 4D were included to predict potential
regulators by using iRegulon software. See experimental procedures for details.
b. GCN5 knockdown impaired IL1α, IL1β and GCLM expression. qPCR was performed
to analyze the mRNA level in control and GCN5 knockdown cells (n=3, mean ± S.E.M.).
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c. GCN5 knockdown abolished glucose-induced H3 K9, K14, K27 and K56 acetylation.
Control and GCN5 knockdown Hep3B cells were glucose-starved for 4 hours and addedback glucose for 2 hours before whole cell extraction for Western blot analysis.
d. Control and GCN5 knockdown MDA 231 cells were treated with glucose and
harvested for Western blot analysis.
e. GCN5 is not required for H3 di-methylation. Control and GCN5 knockdown Hep3B
cells were glucose-starved for 4 hours and added-back glucose for 2 hours before whole
cell extraction for Western blot analysis.
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Third, we found that NEDD4 knockdown impaired the interaction between H3 and GCN5
by using the reciprocal immunoprecipitation assays (Figure 15a and 15b). Notably, GCN5
preferentially binds to mono-ubiquitinated H3 in vivo, indicating that H3 ubiquitination
facilitates the recruitment of GCN5 to H3 (Figure 15a). Fourth, we demonstrated that
glucose induced the interaction between H3 and GCN5 in a H3 ubiquitination-dependent
manner (Figure 15c). Moreover, we showed that recombinant GCN5, when mixing with
ubiquitin in vitro, could interact with ubiquitin efficiently (Figure 15e), demonstrating
that H3 ubiquitination serves as a molecular scaffold to recruit GCN5 to H3. Finally, by
sequential purification assay, we demonstrated that GCN5 and ubiquitinated H3 formed
complex in vivo (Figure 15d), further supporting the interaction between GCN5 and
ubiquitinated H3. To determine whether there is a putative ubiquitin binding motif on
Gcn5, we have created different truncated Gcn5 mutants (Δ aa1-485, Δ aa485-650, Δ
aa650-837) and purified them for in vitro binding assay by mixing with recombinant
GST-ubiquitin proteins. Our data showed that Δ aa485-650 of Gcn5 did not bind to
ubiquitin, while other mutants did bind to ubiquitin, suggesting that aa485-650 of Gcn5
is required for ubiquitin binding (Figure 15f and 15g). These data indicate that aa485-650
may contain a putative ubiquitin-binding region.
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Figure 15 H3 ubiquitination is required for the recruitment of Gcn5.
a, b. NEDD4 knockdown impaired the interaction between GCN5 and H3.3. Transfected
Flag-H3.3 or Flag-GCN5 in Hep3B cells was immunoprecipitated to analyze its coimmunoprecipitates by Western blot.
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c. H3 ubiquitination deficiency impaired the interaction between GCN5 and H3.3. Hep3B
cells were transfected with Flag-H3.3 WT or K23/36/37R for 36 hours, then glucosestarved for 4 hours and added-back glucose for 2 hours. Cells were then lysed for coimmunoprecipitation assay using anti-Flag antibody and subsequent Western blot
analysis.
d. GCN5 and ubiquitinated H3 form complex in vivo. 293T cells were transfected with
Flag-GCN5 and His-Ub as indicated. Briefly, sequential purification is done by first IP
with Flag antibody from whole cell extracts in RIPA buffer. Immunoprecipitates were
then released from antibody/beads by buffer A and followed by in vivo ubiquitination
assay for endogenous H3.
e. GCN5 formed complex with ubiquitin in vitro. See experimental procedures for details.
f, g. Various truncated Flag-GCN5 were purified from mammalian cells for the in vitro
binding assay with GST-Ub.
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To comprehensively understand the dynamic recruitment of acetyltransferase by
H3 ubiquitination, we also examined the recruitment of other known H3
acetyltransferases, p300 and PCAF, by co-immunoprecipitation assay. However, we
found there is no obvious difference between the interaction of p300 or PCAF with WT
H3 and H3 K23/36/37R mutant (Figure 16). In addition, we did not find that NEDD4
knockdown or H3.3 K23/36/37R mutation reduces H3.3 localization on the TSS of IL1A,
IL1B and GCLM genes, which might affect H3 acetylation and gene transcription (Figure
17a to 17c). Also, GCN5 knockdown did not affect H3 ubiquitination (Figure 17d).
Collectively, these results suggest that glucose-induced H3 ubiquitination by NEDD4
specifically regulates the recruitment of GCN5 to H3 for acetylation during transcription.
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Figure 16 H3 ubiquitination on K23/36/37 sites is not required to recruit p300 or
pCAF to histone H3.3.
Stably expressed Flag-H3.3 WT or K23/36/37R was immunoprecipitated from Hep3B
cells to analyze its co-immunoprecipitates by Western blot.
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Gene-specific regulation is usually achieved by the recognition of cis-regulatory
elements on the genome, like glucose responsive elements by trans-regulatory elements,
including glucose activated transcription factors and chromatin remodeling factors. To
know whether NEDD4 conveys gene-specific effect for H3 acetylation, we determined
whether NEDD4 resides in the TSS of its target genes. Chromatin fractionation and ChIPseq assays revealed that NEDD4 does not display chromatin binding (data not shown).
Since H3 ubiquitination is also enriched in nucleoplasm (Figure 17e), H3 ubiquitination
by NEDD4 likely occurs outside of chromatin and gene specificity is likely not conveyed
by the binding of NEDD4 to specific genomic locus. We also asked whether histone
chaperones, which are involved in the nucleosome assembly in the nucleoplasm, regulate
H3 ubiquitination and acetylation. Knockdown of HIRA, the major histone chaperone for
H3.3, did not alter glucose induced H3 ubiquitination and H3 K9 acetylation (Figure 17f),
ruling out the possibility that glucose induced H3 ubiquitination regulates H3 acetylation
and gene transcription through affecting nucleosome assembly and histone deposition. Of
note, disabling H3.3 deposition by HIRA knockdown did not affect glucose induced H3
K9 acetylation (Figure 17f), suggesting that glucose driven H3 acetylation may also occur
mainly in the nucleoplasm. Moreover, NEDD4 knockdown did not affect the binding
between H3.3 and HIRA (Figure 17g). These observations well support our model that
NEDD4 ubiquitinates H3 in the nucleoplasm and in turn regulates H3 acetylation, as
glucose induced H3 ubiquitination is upstream of glucose induced H3 acetylation
occurred in the nucleoplasm.
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Although NEDD4 ubiquitinates H3 in the nucleoplasm, we could detect H3
ubiquitination on chromatin and the localization of H3 ubiquitination at TSS of IL1A,
IL1B and GCLM by sequential ChIP assay (Figure 17h), indicating that ubiquitinated H3
could be deposited into chromatin. Knockdown of NEDD4, which abolished H3
ubiquitination, also blocked glucose induced GCN5 recruitment to chromatin (Figure 17i),
implying that H3 ubiquitination, once deposited into chromatin, may also regulate GCN5
recruitment for glucose induced H3 acetylation at chromatin level.
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Figure 17 H3 ubiquitination occurs at nucleoplasm and does not affect the
incorporation of H3.3.
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a-c. ChIP-qPCR was performed for control and NEDD4 knockdown Hep3B cells.
d. GCN5 knockdown Hep3B cells were subjected to endogenous ubiquitination assay.
e. Immunoprecipitation assay was performed for the Hep3B cells with glucose
treatment.
f. In vivo ubiquitination assay was performed for control and HIRA knockdown Hep3B
cells treated with glucose.
g. Immunoprecipitation assay was performed for control and NEDD4 knockdown
Hep3B cells.
h. Sequential ChIP assay was performed using Re-ChIP-IT→ kit (Active Motif, anti-H3
(Abcam, ab12079), anti-Ub (Thermo scientific, 10H4L21)).
i. Hep3B cells were treated with glucose for indicated times before chromatin
fractionation.
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3.6 Glucose induced H3 ubiquitination by NEDD4 is required for the tumor
sphere formation and tumor engraftment
To understand the biological significance of glucose-induced H3 ubiquitination
by NEDD4, we applied Gene Set Enrichment Analysis (GSEA) to discover enriched gene
sets in microarray data sets. We found that knockdown of NEDD4 profoundly impaired
multiple cancer-related pathways(136) (Figure 18a to 18c), indicating the potential role
of NEDD4 in cancer(115). To evaluate the clinical relevance of this finding, we analyzed
the TCGA exon expression data sets for NEDD4 and top-ranked genes in cancer-related
pathways from microarray (Figure 19a). We found that in multiple cancer types their
expressions were significantly (p<0.05) positively correlated (Figure 19b).
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Figure 18 Nedd4 target genes are enriched for cancer pathways.
a. Multiple functional gene sets are enriched in control versus NEDD4 knockdown
Hep3B cells.
b, c. Enrichment map view of gene set enrichment analysis results.
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Figure 19 Nedd4 target genes is correlated with Nedd4 in the TCGA data sets.
a. Heat map view of top gene list of cancer-related gene sets.
b. Heat map view of the TCGA exon expression profile for the NEDD4 and NEDD4
target genes from cancer-related gene sets. Patient samples ranked tops or bottoms 30%
for NEDD4 expression were included and rank listed. Wilcoxon test was performed to
evaluate the correlation of gene expression between NEDD4 and each gene. Significant
(p<0.01) positive correlations were shown in red and negative correlations were show in
green.
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This observation led us to hypothesize that glucose-induced H3 ubiquitination by
NEDD4 may have a critical role in cancer regulation. To test this hypothesis, we
determined whether Aldh+ population and sphere forming ability are affected by glucoseinduced H3 ubiquitination by NEDD4. Notably, we found that in vitro tumor sphere
numbers and Aldh+ cell population were reduced upon glucose depletion, NEDD4
knockdown, NEDD4 tyrosine phosphorylation deficient mutation, GCN5 knockdown,
H3.3 knockdown and deficiency of H3 ubiquitination (Figure 20a to 20p).
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Figure 20 H3 ubiquitination is required for the maintenance of cancer stem cells.
a. Glucose deprivation abolished in vitro tumor sphere formation for Hep3B cells.
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b-p. NEDD4, H3.3, Gcn5, H3 ubiquitination and Nedd4 phosphorylation are required for
in vitro tumor sphere formation and maintaining Aldh+ cell population. Cells were
analyzed by in vitro tumor sphere forming assay (See experimental procedures for details).
Data were presented as the mean number of three biological replicates ± S.E.M. Cells
were stained for Aldh enzymatic activity and analyzed by flow cytometry. Data were
presented as the mean percentage of three biological replicates ± S.E.M.
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To further examine the in vivo function, 1000 Aldh+ cells were subcutaneously
injected into nude mice to evaluate the in vivo tumor engraftment frequency. We found
that knockdown of NEDD4 or H3 K23/36/37R mutation reduced the tumor incidence and
average tumor size, suggesting that NEDD4-mediated H3 ubiquitination is also required
for the tumorigenecity of Aldh+ cells in vivo (Figure 21a to 21h). Together, these studies
reveal an important role of glucose-induced H3 ubiquitination by NEDD4 in cancer
development.
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Figure 21 H3 ubiquitination is required for the in vivo engraftment of cancer stem
cells.
a-c. NEDD4 knockdown reduced in vivo tumor engraftment frequency. Shown were
tumor image, tumor incidence and tumor size, which was presented as the mean volume
of tumors ((L x W x W)/2) ± S.E.M. See experimental procedures for details.
d-f. K23/36/37R mutation reduced in vivo tumor engraftment frequency. Shown were
tumor image, tumor incidence and tumor size, which was presented as the mean volume
of tumors ((L x W x W)/2) ± S.E.M. See experimental procedures for details.
g, h. Shown are the mice image of xenograft model.
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3.7 IL1α/IL1β and reaction oxygen species (ROS) homeostasis are critical
for tumor sphere formation
We next determined which set of target genes is involved in tumor sphere
formation. As we have already identified IL1α, IL1β and GCLM as transcriptional targets
(Fig. 4e and 4l), we investigated whether any of these genes may be involved in tumor
sphere formation. While neutralizing extracellular IL1α and IL1β individually had little
impact on tumor sphere formation in vitro, simultaneous sequestering of IL1α and IL1β
resulted in a drastic reduction of tumor sphere numbers (Figure 22a and 22c), suggesting
that IL1α and IL1β are required, but likely compensate each other, for maintaining tumor
sphere formation ability. Interestingly, we also found that the treatment of IL1β could not
fully rescue the defect in tumor sphere formation upon NEDD4 knockdown, despite that
IL1β alone readily increased the tumor sphere numbers in control cells (Figure 22b and
22d), indicating that there are other important factors involved. As excess of ROS has
deleterious impact on cancer cells(144), we rationalized that loss of GCLM, which is a
key enzyme subunit in the biosynthesis of anti-oxidant glutathione (GSH), may lead to
ROS elevation and subsequent inhibition of tumor sphere formation. In line with this
assumption, we found that the knockdown of NEDD4 or deficiency of H3 ubiquitination,
which impaired GCLM expression, increased cellular ROS level and decreased GSH
level (Figure 22e to 22g). Treatment of NAC, a widely used ROS scavenger, not only
increased tumor sphere number in control cells, but also partially rescued NEDD4
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knockdown phenotype (Figure 22b and 22d). Remarkably, co-administration of NAC and
IL1β completely rescued the defect in tumor sphere formation upon NEDD4 knockdown
(Figure 22b and 22d), suggesting both IL1β and anti-oxidant are critical for tumor sphere
formation. Together, these results reveal that IL1α, IL1β and GCLM are critical
downstream mediators of H3 ubiquitination signaling in cancer regulation.
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Figure 22 IL1A, IL1B and GCLM are important cancer stem cell factors.
a. Simultaneous neutralization of IL1α and IL1β abolished in vitro tumor sphere
formation. Anti-IL1α (1:200) and anti-IL1β (1:200) neutralizing antibodies were added
to medium on day 1 and day 4 after seeding Hep3B cells for in vitro tumor sphere-forming
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assay. Data are presented as the mean number of three biological replicates ± S.E.M. See
Fig. S7A and experimental procedures for details.
b. IL1β and NAC co-treatment rescued the defect of NEDD4 knockdown in the in vitro
tumor sphere formation. Control and NEDD4 knockdown Hep3B cells were treated with
recombinant IL1β and/or NAC (0.5mM) in the in vitro tumor sphere-forming assay. Data
were presented as the mean number of three biological replicates ± S.E.M. See Fig. S7B
and experimental procedures for details.
c, d. Treatment schemes and images of tumor sphere formation assay.
e, f. NEDD4 and H3 ubiquitination are required for the maintenance of cellular ROS.
Control and NEDD4 knockdown or H3.3 WT or K23/36/37R restored Hep3B cells were
stained by DCFDA for cellular ROS and subjected to flow cytometry analysis. Data were
presented as the mean DCFDA signals of three biological replicates ± S.E.M.
g. GSH level is reduced in NEDD4 knockdown cells. Control and NEDD4 knockdown
Hep3B cells were collected and GSH levels were measured by a colorimetric enzymatic
reaction. Data were presented as the mean value of three biological replicates ± S.E.M.
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Chapter 4 Discussion and Future Plans
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Histone acetylation is generally a mark for active transcription. In eukaryote,
glucose generally enhances H3 acetylation through the glucose downstream metabolite
acetyl-CoA. However, it is unclear whether this metabolite-driven H3 acetylation is also
under the control of glucose mediated cellular signaling. In this study, we uncover that
glucose-induced H3 ubiquitination by NEDD4 specifically recruits GCN5 for H3
acetylation, which is required for the transcription of important tumor sphere forming
factors (Figure 23). This discovery inspired us to study which downstream metabolites
are required for the full activation of H3 acetylation induced by glucose. Notably, our
data suggest that not only acetyl-CoA, but also H3 ubiquitination driven by glucose
mediated ATP production and NEDD4 activation is required for H3 acetylation,
extending our concepts on how glucose precisely induced H3 acetylation. Although we
found that glucose induced H3 acetylation should mainly occur in the nucleoplasm, we
surprisingly found that glucose-induced H3 acetylation is still enriched at TSS or
enhancers by ChIP-seq and largely correlated with glucose induced gene expression
pattern, suggesting that glucose may just amplify the existing basal level of acetylation at
specific loci. Based on these observations, we speculate that the global induction of H3
acetylation by glucose shown in our western blot analysis may likely reflect the
summation of gene/genomic locus specific decoration of histone H3 acetylation marks,
which are first conjugated to H3 in the nucleoplasm and then deposited into chromatin at
designated loci with the help of chromatin remodelers or histone chaperones.
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NEDD4 in many occasions is identified as a cytosolic E3 ligase, which targets its
protein substrates mostly for ubiquitination and proteasome degradation(115). Our study
reveals for the first time the non-proteolytic role of NEDD4 in nucleus. We show that
NEDD4 is presented in both cytoplasm and nucleus under normal conditions. Glucose
treatment on glucose-starved cells triggers NEDD4 Y43/585 phosphorylation for its E3
ligase activation, providing an explanation as to why H3 ubiquitination is enhanced by
glucose treatment. Moreover, we also identify that NEDD4 mono-ubiquitinates H3 at
multiple sites, consistent with the capability of NEDD4 in triggering mono-ubiquitination
on its substrates as IGF1R and IRS2(117, 145). We also found that NEDD4 did not
display chromatin binding, which is consistent with the data indicating that glucose
induced H3 acetylation may also occur mainly in the nucleoplasm. Although NEDD4 has
been implicated in regulating AKT signaling(120, 121) and AKT signaling may also
participate in the regulation of H3 acetylation(146), we did not find that AKT signaling
is affected by NEDD4 knockdown in our glucose treatment and sphere forming
experiments (Figure 24a and 24b). Interestingly, AKT phosphorylation is negatively
correlated with the glucose action on H3 acetylation (Fig. S24a), which opposes the
previous finding(146), revealing that the correlation between AKT phosphorylation and
H3 acetylation could be altered under distinct stimuli(146). Thus, our finding showing
NEDD4 regulates H3 acetylation and tumor sphere is unlikely through AKT signaling
pathway. These results further extended the versatile role of NEDD4 in cellular signaling.
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Many HATs, such as GCN5, PCAF, p300/CBP, and RTT109, are shown to
catalyze H3 acetylation on the N-terminal tail(36, 37). Each of these HATs has its own
preferred acetylation sites on H3. Although histone acetylation by HATs generally
promotes transcriptional activation, it is unclear how those HATs are differentially
utilized and how differential H3 acetylation patterns are established upon various
stimulations. In this study, we found that under glucose stimulation conditions GCN5
specifically acetylates K9, K14 and K27 on H3. More importantly, H3 ubiquitination by
NEDD4 specifically recruits GCN5, but not PCAF and p300 for H3 acetylation upon
glucose stimulation. Of note, H3 acetylation on K23 and K36, which are H3
ubiquitination sites, are not triggered by glucose, supporting our model that these lysine
sites are reserved for H3 ubiquitination under glucose stimulation condition to convey
specificity for HAT recruitment. While it is thus far unclear why cells prefer to utilize
GCN5 or its H3 acetylation sites for glucose-induced gene transcription activation,
warranting for further explorations for HAT specificity under various stresses and/or
stimuli, our findings collectively provide great insights into the glucose-induced histone
acetylation.
Tumor sphere can be formed by a subgroup of cancer cells that possesses normal
stem cells like characteristic and likely responsible for tumor initiation, drug resistance,
relapse and metastasis(72, 73, 97-99). These traits are generally originated from abnormal
genetic or epigenetic alteration, including histone modification. Our study provides
evidences that glucose-induced H3 ubiquitination as well as other components in this
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pathway, namely NEDD4, H3.3 and GCN5, play critical roles in maintaining such
population of cancer cells. Moreover, by ChIP-seq and microarray analysis we found that
IL1α, IL1β and GCLM are target genes of glucose-induced H3 ubiquitination. Notably,
we experimentally demonstrate that maintenance of tumor sphere forming cells requires
both IL1α/IL1β and cellular ROS homeostasis. Thus in the glucose context, our results
indicate that increased glucose demand in cancer cells is a prerequisite not only for
producing more anti-oxidants, energy and cellular building blocks, but also for activating
important cellular signaling to maintain H3 ubiquitination and acetylation, thereby
driving transcription activation for crucial tumor sphere forming factors. Our findings
further emphasize the important role of glucose in tumor sphere forming cells and provide
a renovated view for glucose in the maintenance of tumor sphere forming cells.
In summary, our study established a new role of glucose in transcriptome
reprogramming, tumor sphere forming and tumor engraftment through NEDD4dependent H3 ubiquitination and subsequent GCN5-mediated H3 acetylation (Figure 23).
Hence, targeting NEDD4 and GCN5 or their transcriptional targets such as IL1α, IL1β
and GCLM may be promising approaches for cancer therapy.
Since there are still some unsolved mysteries left in my study, I’d like to point out
the future direction. NEDD4 deficiency affects H3 acetylation and transcription of
selected genes, but NEDD4 does not bind to chromatin. Thus the chromatin localized H3
ubiquitination may convey the gene specificity of NEDD4. Of note, sequential ChIP of
ubiquitinated H3 shown its localization at the TSS of IL1A, IL1B and GCLM, indicating
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that H3 ubiquitination may be localized at glucose target genes. However, to provide
convincing evidence, it is better to generate specific antibody for H3 ubiquitination at
either K23, 36 or 37 site. Using this antibody, we could perform ChIP-seq analysis to
examine the genome wide localization of H3 ubiquitination and examine whether it is
induced by glucose and colocalized with H3 acetylation at specific genes on chromatin.
If this is the case, it remains to be answered that how H3 ubiquitination is deposited into
chromatin in a gene specific manner. This might be achieved by transcription
factor/histone chaperone coupled deposition of H3.3. To identify this mechanism, there
might be two screening methods. First, we could use bioinformatics to search for the
potential transcription factors that have similar binding genes with glucose induced H3
ubiquitination and/or H3 acetylation. Secondly, we could pull down ubiquitinated H3
using specific antibody that we generated and identify its binding proteins, which may be
potential chaperones or transcription factors that mediate the gene specific deposition.
Since LncRNA is reported to mediated gene specific regulation of chromatin factors, we
should also test whether LncRNA may regulate gene specific deposition of H3
ubiquitination and provide molecular adapters for ubiquitin recognition. Together, this
may provide more insights into how glucose induces H3 acetylation at specific loci and
answer the major remaining question left in my thesis project.
Another important question is that how exactly glucose induces Nedd4 activation,
which may be through tyrosine phosphorylation of Nedd4. Since pyruvate or ATP is not
responsible for this, we would like to test which downstream metabolites of glucose or
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glucose per se is important for the activation of Nedd4. There might be several
possibilities. It has been reported that glucose elicited signaling from hexokinase when
binding to it (147), the pathway of which is still not been identified and may convey
kinase activity towards Nedd4. It would be also interesting to test whether glucose
directly binds to any other proteins to activate Nedd4 E3 ligase activity, which is an
interesting area to explore, since the direct sensing mechanism of glucose is not well
understood in the human cells. As a well-established method in the plant biology and
microbiology, we could screen glucose binding proteins by sepharose beads, the free
saccharide ends of which are the immobilized glucose molecules. It is also possible that
Nedd4 activation is mediated by the downstream metabolite of glucose that is upstream
of pyruvate. However, those metabolites are mostly not permeable to plasma membrane,
and could not be simply tested by treating the cells in the medium. Thus developing a
membrane free in vitro system to test H3 acetylation is important for testing which
metabolite is critical. In addition, since the E3 ligase activity of Nedd4 Y43/585E could
be further enhanced by glucose, it is also possible that other mechanisms are involved in
the glucose induced Nedd4 activation. Nedd4 is known to be activated by cellular calcium,
which opens up the auto inhibitory formation of Nedd4. It is also implicated that glucose
could increase calcium level in the pancreatic β-cells, thus a universal mechanism
whether glucose increases calcium level in cancer cells should be determined and how
glucose elevates cellular calcium level should be further identified.
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In the future, it would be also interesting to systematically study how glucose
induced H3 acetylation is regulated. CRISPR/Cas9 is a new technology that enabled the
researchers to knockout genes in almost any given cell lines. The CRISPR knockout
library covering all known human genes represents a powerful tool for functional
screening, since its capability to suppress gene expression is many fold higher than
traditional shRNA. By coupling FACS and next generation sequencing (NGS), we could
first sort the cells with decreased H3 acetylation signal induced by glucose in the pooled
library infected cells and then distinguish the enriched knockout Cas9 clones with NGS.
Candidates from this screening would provide global information about how H3
acetylation is regulated by the input from any other cellular signaling.
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